Methods and antibody compositions for the treatment of cancer

LSR-targeted ADCs provide an effective treatment for TNBC by specifically binding to LSR, achieving tumor reduction and metastasis control with reduced side effects.

WO2026236308A1PCT designated stage Publication Date: 2026-11-12OHIO STATE INNOVATION FOUND
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026820
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-29
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current cancer treatments, particularly for triple-negative breast cancer (TNBC), suffer from limited efficacy, severe side effects, and drug resistance, with a lack of effective targeted therapies due to the absence of promising cell surface receptors.

Method used

Development of a Lipolysis-stimulated lipoprotein receptor (LSR)-targeted monoclonal antibody-drug conjugates (ADCs) that specifically bind to LSR, conjugated with chemotherapeutic and immunotherapy agents, to target and treat various cancers, including TNBC.

Benefits of technology

The LSR-targeted ADCs demonstrate significant cytotoxicity and tumor growth inhibition in TNBC models, reducing tumor volume and metastasis while minimizing side effects on normal tissues.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026026820_12112026_PF_FP_ABST
    Figure US2026026820_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed herein are antibodies that bind to Lipolysis-stimulated lipoprotein receptor (LSR). Antibody-drug conjugates comprising an anti-LSR monoclonal antibody and a pharmaceutically active agent, such as an chemotherapeutic agent are also disclosed. Dual antibody-drug conjugates comprising an anti-LSR monoclonal antibody conjugated to at least two pharmaceutically active agents, such as a chemotherapeutic agent and an immunotherapy agent are also disclosed. Methods of treating cancer and conditions or diseases sensitive to LSR inhibition are disclosed.
Need to check novelty before this filing date? Find Prior Art

Description

Docket No: T2025-304PCT (069596.00133)METHODS AND ANTIBODY COMPOSITIONS FOR THE TREATMENT OF CANCERCROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority under 35 U. S. C. § 119 to U. S. Provisional Patent Application No. 63 / 801,350 filed May 7, 2025 and to U. S. Provisional Patent Application No. 63 / 813,771 filed May 29, 2025, each of which is hereby incorporated by reference in its entirety.STATEMENT OF GOVERNMENT INTEREST

[0002] This invention was made with government support under R01 CA242917 awarded by the National Institutes of Health. The government has certain rights in the invention.INCORPORATION BY REFERENCE OF SEQUENCE LISTING

[0003] The material in the accompanying sequence listing is hereby incorporated by reference in its entirety into this application. The accompanying file, named 069596.00133, was created on April 27, 2026 and is 16kB.FIELD

[0004] This disclosure is generally in the area of treatment of cancer and in the area of Lipolysis-stimulated lipoprotein receptor (LSR)-targeted mAb and antibody-drug conjugates (ADC), including dual-ADCs, useful in the treatment of cancer, including tumor treatment.BACKGROUND

[0005] Cancer is a major public health burden that is the second leading cause of death in the United States, leading to over 600,000 deaths in 2024, and an estimated 2 million new cases. Common cancer treatments include surgery, radiation, and chemotherapy, alone or in combination. Current treatments have numerous shortcomings, including lack of efficacy and significant side effects.

[0006] In particular, triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype (ER- / PR- / HER2-), is characterized by rapid growth, high metastasis rate and frequent recurrence, with the poorest prognosis compared to all other breast cancer subtypes. Standard cytotoxic chemotherapies, such as doxorubicin and paclitaxel, have limited clinicalDocket No: T2025-304PCT (069596.00133)benefits due to severe side effects, emergence of drug resistance, and high recurrence rates. Immune checkpoint blockers, including the anti-PD-1 orPD-Ll therapies pembrolizumab, durvalumab, nivolumab, and atezolizumab, show low response rates of 5.3-24.0% and are frequently associated with acquired drug resistance in TNBC patients. Sacituzumab govitecan-hziy (Trodelvy), a trophoblast cell-surface antigen 2 (Trop-2)-targeting antibody-SN-38 conjugate has been developed to treat relapsed or refractory TNBC and other cancers following standard therapies. With limited treatment options, there is an urgent need to develop new targeted therapies for TNBC, which have a variety of subtypes, including basal -like 1 (BL1), basal-like 2 (BL2), mesenchymal-like (M), mesenchymal stem-like (MSL), and luminal androgen receptor (LAR), among others.

[0007] Lipolysis- stimulated lipoprotein receptor (LSR) is expressed in the plasma membrane, cytoplasm and nucleus of cancer tissues with metastatic signatures. Elevated LSR levels generally correlate with poor disease-free survival in breast cancer patients. LSR supports lipid metabolism, promotes tumor growth, defines cell comers to form tricellular tight junctions in epithelial cells, and contributes to cancer cell proliferation and metastasis.

[0008] The development of targeted therapies for a variety of cancers using antibody-drug conjugates (ADCs), has been limited by the lack of promising cell surface receptors, especially for TNBC.

[0009] Thus, with the shortcomings of current treatments for cancer, such as endometrial, gastric, breast cancer, including triple negative breast cancer, and endothelial cancer, including ovarian cancer, there is a need for improved anti-cancer therapies.SUMMARY

[0010] In one aspect, provided herein is an isolated monoclonal antibody, comprising: a heavy chain variable region (VH); and a light chain variable region (VL); wherein the VH comprises a first heavy chain complementarity determining region (HCDR1), a second heavy chain complementarity determining region (HCDR2), and a third heavy chain complementarity determining region (HCDR3); wherein the VL comprises a first light chain complementarity determining region (LCDR1), a second light chain complementarity determining region (LCDR2), and a third light chain complementarity determining region (LCDR3); and wherein HCDR1 comprises a sequence with at least 80% identity to SEQ ID NO: 3, HCDR2 comprises aDocket No: T2025-304PCT (069596.00133)sequence with at least 80% identity to SEQ ID NO: 4, and HCDR3 comprises a sequence with at least 80% identity to SEQ ID NO: 5, and LCDR1 comprises a sequence with at least 80% identity to SEQ ID NO: 10, LCDR2 comprises the amino acid sequence YTS, and LCDR3 comprises a sequence with at least 80% identity to SEQ ID NO: 12. In some embodiments, the VH comprises a sequence with at least 80% identity to the sequence set forth as SEQ ID NO: 1; and / or the VL comprises a sequence with at least 80% identity to the sequence set forth as SEQ ID NO: 8. In some embodiments, the VH constant region comprises a sequence with at least 80% identity to the sequence set forth as SEQ ID NO: 2; and / or the VL constant region comprises a sequence with at least 80% identity to the sequence set forth as SEQ ID NO: 9. In other embodiments, the antibody is a human antibody. In some variations of any aspect or embodiment, the antibody binds to Lipolysis-Stimulated Lipoprotein Receptor (LSR).

[0011] In one aspect, the present application discloses an isolated antigen binding fragment of the antibody disclosed herein, wherein the antigen binding fragment comprises any variation of HCDR1, HCDR2, and HCDR3; and / or LCDR1, LCDR2, and LCDR3; and / or the VH and / or the VL of the antibody as disclosed herein.

[0012] In another aspect, an isolated nucleic acid molecule encoding any disclosed antibody or antigen binding fragment is provided herein. In some embodiments, the isolated nucleic acid molecule comprises (a) a DNA sequence at least 80% identical to the sequence set forth as SEQ ID NO: 6 and / or (b) a DNA sequence at least 80% identical to the sequence set forth as the amino acid sequence set forth as SEQ ID NO: 13.

[0013] In another aspect, a composition is provided herein, comprising an effective amount of a disclosed monoclonal antibody or antigen binding fragment; and a pharmaceutically acceptable carrier.

[0014] In one aspect, provided herein is an antibody-drug conjugate comprising a disclosed monoclonal antibody conjugated to a first pharmaceutically active agent via a first bivalent linker. In one embodiment, the monoclonal antibody is also conjugated to a second pharmaceutically active agent via a second bivalent linker. In some embodiments, the first pharmaceutically active agent is a chemotherapeutic agent. In some embodiments, the second pharmaceutically active agent is an immunotherapy agent.

[0015] In another aspect, disclosed herein is a pharmaceutical composition comprising any conjugate disclosed herein and a pharmaceutically acceptable carrier.Docket No: T2025-304PCT (069596.00133)

[0016] In another aspect, disclosed herein is a method of treating a disease susceptible to LSR inhibition in a patient in need thereof, wherein the method comprises administering to the patient a therapeutically effective amount of any antibody, conjugate or composition disclosed herein. In some embodiments, the method comprises treating cancer, including, for example endometrial, gastric, breast cancer, or epithelial cancer.BRIEF DESCRIPTION OF THE FIGURES

[0017] FIG. 1A is an image of IHC staining of TNBC patient tissue microarray (TMA) with engineered anti-LSR antibody, n = 110.

[0018] FIG. IB are representative images of normal breast and TNBC tissues with low, medium and high levels of LSR expression.

[0019] FIG. 1C is a graphical representation of TCGA transcript analysis of LSR expression of normal breast and breast cancers.

[0020] FIG. ID is an image of Western blotting of TNBC cell lines (MDA-MB-231, MDA-MB-468, 4T1) and normal breast epithelial cell (184B5).

[0021] FIG. 2A is a graphical representation of clone ranking of murine anti-human LSR mAb.

[0022] FIG. 2B is a is a schematic of the engineering of LSR mAb by fusing the variable region of the murine anti-human LSR mAb with the constant region of human IgG.

[0023] FIG. 2C is a graphical representation of the transient production of engineered LSR mAb using HEK293 cells.

[0024] FIG. 2D is a graphical representation of the purification of engineered LSR mAb using protein A column with liquid chromatography.

[0025] FIG. 3A is a graphical representation of flow cytometry of an LSR mAb surface binding to TNBC cells: MDA-MB-468, MDA-MB-231 and 4T1.

[0026] FIG. 3B are images from a confocal microscope showing internalization of mAb (Cy5.5) in MDA-MB-468 cells (GFP).

[0027] FIG. 3C are images from IVIS imaging of MDA-MB-231 xenografted NSG mice with administration of LSR mAb-Cy5.5. About 80 pg of mAb was injected via tail vein.

[0028] FIG. 3D are images from ex vivo imaging with IVIS, validating TNBC specificity.Docket No: T2025-304PCT (069596.00133)

[0029] FIG. 4A is a schematic structure of an antibody drug conjugate (ADC): LSR mAb-DM1.

[0030] FIG. 4B is a graphical representation of HPLC data to confirm conjugation of mAb and drug in the ADC.

[0031] FIG. 4C is an image of SDS-PAGE data, showing ADC integrity. M: Marker; 1: LSR mAb; 2: LSR mAb-DMl.

[0032] FIG. 4D is a mass spectrometry plot of mass (kDa) vs intensity (%) showing DAR (3.91) analysis of ADC.

[0033] FIG. 4E is a graphical representation of DM1 concentration vs relative viability, showing the cytotoxicity of free DM1 in TNBC 4T1, MDA-MB-231 and MDA-MB-468. n = 3.

[0034] FIG. 4F is a graphical representation of ADC concentration vs relative viability, showing the cytotoxicity of LSR mAb-DMl in TNBC 4T1, MDA-MB-231 and MDA-MB-468. n = 3. *P<0.005.

[0035] FIG. 5A is a graphical representation of the growth in tumor volume over days, showing the tumor volume profile by black arrow in each of saline, anti-LSR, ADC at 12 mg / kg and ADC at 24 mg / kg. n = 6. Data were presented as mean ± SEM, n = 6. *P<0.05 vs. saline using ANOVA followed by Dunnetf s t-test.

[0036] FIG. 5B is a graphical representation of the tumor fluorescence flux measured with IVIS.

[0037] FIG. 5C are images from IVIS imaging of mice on Days 9 and 31.

[0038] FIG. 5D are images of H& E staining of harvested tumors. Scale bar equals 20 pm.

[0039] FIG. 5E are images of IHC staining of tumor tissues with Ki67 antibody. Scale bar equals 20 pm.

[0040] FIG. 6A is a graphical representation of the tumor volume profiles with saline and ADC. Black arrow indicating i.v. injection, n = 4. Data were presented as mean ± SEM, n = 6. *P<0.05 vs. saline using ANOVA followed by Dunnett’s t-test.

[0041] FIG. 6B is a graphical representation of Body weight with saline and ADC.

[0042] FIG. 6C are images from IVIS imaging of mice on Day 17.

[0043] FIG. 6D are images of H& E staining of tumor tissue indicating apoptosis and cell death of TNBC in treatment group. Scale bar equals 20 pm.Docket No: T2025-304PCT (069596.00133)

[0044] FIG. 6E are images of IHC staining of tumor tissues with Ki67 (cell proliferation inhibition) and CCasp3 (apoptosis) antibodies. Scale bar equals 20 pm.

[0045] FIG. 6F are images showing the effect of LSR mAb to reduce lipid droplets in MDA-MB-231 cells.

[0046] FIG. 7A is a graphical representation of the body weight of mice administered saline, mAb, ADC @12 mg / kg and ADC @24 mg / kg. n = 6.

[0047] FIG. 7B are images of H& E staining of major organs (heart, liver, spleen, lung, kidney, and brain) upon treatment with saline or ADC @24 mg / kg. Scale bar equals 20 pm.

[0048] FIG. 7C are images of IHC staining of 33 human normal organs, including cerebrum, cerebellum, peripheral nerve, adrenal gland, thyroid gland, spleen, thymus, bone marrow, lymph node, tonsil, pancreas, liver, esophagus, stomach, small intestine, colon, lung, salivary, pharynx, kidney, bladder, testis, prostate, penis, ovary, uterine tube, breast, endometrium, cervix, cardiac muscle, skeletal muscle, mesothelium and skin, n = 2.

[0049] FIG. 7D are images of IHC staining of representative major organs. Scale bar equals 20 pm.

[0050] FIG. 8 is a schematic for the preparation of a dual antibody-drug conjugate (dual ADC).DETAILED DESCRIPTION

[0051] Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.

[0052] As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure.

[0053] Any recited method can be carried out in the order of events recited or in any other order that is logically possible. That is, unless otherwise expressly stated, it is in no way intended that any method or aspect set forth herein be construed as requiring that its steps be performed in a specific order. Accordingly, where a method claim does not specifically state in the claims or descriptions that the steps are to be limited to a specific order, it is no way intended that an order be inferred, in any respect. This holds for any possible non-express basis for interpretation,Docket No: T2025-304PCT (069596.00133)including matters of logic with respect to arrangement of steps or operational flow, plain meaning derived from grammatical organization or punctuation, or the number or type of aspects described in the specification.

[0054] All publications and patents cited in this specification are cited to disclose and describe the methods and / or materials in connection with which the publications are cited. All such publications and patents are herein incorporated by references as if each individual publication or patent were specifically and individually indicated to be incorporated by reference. Such incorporation by reference is expressly limited to the methods and / or materials described in the cited publications and patents and does not extend to any lexicographical definitions from the cited publications and patents. Any lexicographical definition in the publications and patents cited that is not also expressly repeated in the instant application should not be treated as such and should not be read as defining any terms appearing in the accompanying claims. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates of publication provided could be different from the actual publication dates that may need to be independently confirmed.

[0055] While aspects of the present disclosure can be described and claimed in a particular statutory class, such as the system statutory class, this is for convenience only and one of skill in the art will understand that each aspect of the present disclosure can be described and claimed in any statutory class.

[0056] It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosed compositions and methods belong. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the specification and relevant art and should not be interpreted in an idealized or overly formal sense unless expressly defined herein.

[0057] The presently disclosed subject matter will now be described more fully hereinafter. However, many modifications and other embodiments of the presently disclosed subject matter set forth herein will come to mind to one skilled in the art to which the presently disclosedDocket No: T2025-304PCT (069596.00133)subject mater pertains having the benefit of the teachings presented in the foregoing descriptions. Therefore, it is to be understood that the presently disclosed subject matter is not to be limited to the specific embodiments disclosed and that modifications and other embodiments are intended to be included within the scope of the appended claims. In other words, the subject matter described herein covers all alternatives, modifications, and equivalents. In the event that one or more of the incorporated literature, patents, and similar materials differs from or contradicts this application, including but not limited to defined terms, term usage, described techniques, or the like this application controls. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in this field. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.

[0058] Aspects of the present disclosure will employ, unless otherwise indicated, techniques of molecular biology, microbiology, organic chemistry, biochemistry, physiology, cell biology, blood vessel biology, and the like, which are within the skill of the art. Such techniques are explained fully in the literature.

[0059] Prior to describing the various aspects of the present disclosure, the following definitions are provided and should be used unless otherwise indicated. Additional terms may be defined elsewhere in the present disclosure.DEFINITIONS

[0060] All ranges disclosed herein are to be understood to encompass any and all subranges subsumed therein. For example, a stated range of “1.0 to 10.0” should be considered to include any and all subranges beginning with a minimum value of 1.0 or more and ending with a maximum value of 10.0 or less, e.g., 1.0 to 5.3, or 4.7 to 10.0, or 3.6 to 7.9. All ranges disclosed herein are also to be considered to include the end points of the range, unless expressly stated otherwise. For example, a range of “between 5 and 10,” “from 5 to 10,” or “5-10” should generally be considered to include the end points 5 and 10.

[0061] Further, when the phrase “up to” is used in connection with an amount or quantity, it is to be understood that the amount is at least a detectable amount or quantity. For example, a material present in an amount “up to” a specified amount can be present from a detectable amount and up to and including the specified amount.Docket No: T2025-304PCT (069596.00133)

[0062] Furthermore, the terms "substantially," "approximately," and "about," as used herein when referring to a measurable value such as an amount of agent of this invention, dose, time, temperature, and the like, is meant to encompass variations of ±20%, ±10%, ±5%, ±1%, ±0.5%, or even ±0.1% of the specified amount. The term "consists essentially of (and grammatical variants) shall be given its ordinary meaning and shall also mean that the composition or method referred to can contain additional components as long as the additional components do not materially alter the composition or method. The term "consists of (and grammatical variants) shall be given its ordinary meaning and shall also mean that the composition or method referred to is closed to additional components. The term "comprising" (and grammatical variants) shall be given its ordinary meaning and shall also mean that the composition or method referred to is open to contain additional components.

[0063] It is also to be understood that the article "a" or "an" refers to "at least one," unless the context of a particular use requires otherwise.

[0064] Also as used herein, "and / or" refers broadly to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative ("or").

[0065] Terms such as “at least one of A and B” should be understood to mean “only A, only B, or both A and B.” The same construction should be applied to longer list (e.g., “at least one of A, B, and C”).

[0066] The term "effective amount," as used herein, refers broadly to that amount of a recited agent effective to treat, prevent, or reduce the severity or progression of a disorder in a subject, such as a human subject. This includes improving the subject's condition (e.g., in one or more symptoms), delaying or reducing the progression of the disease and / or disorder, preventing or delaying the onset of the disorder, and / or changing clinical parameters, disease or illness, etc., as would be well known in the art. For example, an effective amount can refer to the amount of a composition or agent that improves a condition in a subject by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100%.

[0067] As used herein, the terms "treating," "treatment," and the like are used to mean obtaining a desired pharmacologic and / or physiologic effect. The effect may be prophylactic inDocket No: T2025-304PCT (069596.00133)terms of completely or partially preventing a disorder or sign or symptom thereof, and / or may be therapeutic in terms of a partial or complete cure for a disorder and / or adverse effect attributable to the disorder, or the relief or elimination of a symptom thereof. Thus, treatment includes preventing or protecting against the disease or disorder, that is, causing the clinical symptoms not to develop; and / or inhibiting the disease or disorder, that is, arresting or suppressing the development of clinical symptoms; and / or relieving the disease or disorder that is, causing the regression of clinical symptoms; and / or reducing the metastasis of the primary tumor or cancer.

[0068] By “reduce” or other forms of the word, such as “reducing” or “reduction,” is meant lowering of an event or characteristic (e.g., tumor growth). It is understood that this is typically in relation to some standard or expected value, in other words it is relative, but that it is not always necessary for the standard or relative value to be referred to. For example, “reduces tumor growth” means reducing the rate of growth of a tumor relative to a standard or a control (e g., an untreated tumor).

[0069] The “patient” or “subject” treated as disclosed herein is, in some embodiments, a human patient, although it is to be understood that the principles of the presently disclosed subject matter indicate that the presently disclosed subject matter is effective with respect to all vertebrate species, including mammals, which are intended to be included in the terms “subject” and “patient.” Suitable subjects are generally mammalian subjects. The subject matter described herein finds use in research as well as veterinary and medical applications. The term “mammal” as used herein includes, but is not limited to, humans, non-human primates, cattle, sheep, goats, pigs, horses, cats, dog, rabbits, rodents (e.g., rats or mice), monkeys, etc. Human subjects include neonates, infants, juveniles, adults and geriatric subjects. The subject “in need of’ the methods disclosed herein can be a subject that is experiencing a disease state and / or is anticipated to experience a disease state, and the methods and compositions of the invention are used for therapeutic and / or prophylactic treatment.

[0070] Antibody and Antigen Binding Fragment: An immunoglobulin, antigen-binding fragment, or derivative thereof, that specifically binds and recognizes an analyte (antigen) such as LSR. The term “antibody” is used herein in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antigen binding fragments, so long as they exhibit the desired antigen-binding activity.Docket No: T2025-304PCT (069596.00133)

[0071] Non-limiting examples of antibodies include, for example, intact immunoglobulins and variants and fragments thereof that retain binding affinity for the antigen. Examples of antigen binding fragments include but are not limited to Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g. scFv); and multispecific antibodies formed from antibody fragments. Antibody fragments include antigen binding fragments either produced by the modification of whole antibodies or those synthesized de novo using recombinant DNA methodologies (see, e.g., Kontermann and Dubel (Eds.), Antibody Engineering, Vols. 1-2, 2' ed., Springer-Verlag, 2010).

[0072] Antibodies also include genetically engineered forms such as chimeric antibodies (such as humanized murine antibodies) and heteroconjugate antibodies (such as bispecific antibodies).

[0073] An antibody may have one or more binding sites. If there is more than one binding site, the binding sites may be identical to one another or may be different. For instance, a naturally-occurring immunoglobulin has two identical binding sites, a single-chain antibody or Fab fragment has one binding site, while a bispecific or bifunctional antibody has two different binding sites.

[0074] Typically, a naturally occurring immunoglobulin has heavy (H) chains and light (L) chains interconnected by disulfide bonds. Immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable domain genes. There are two types of light chain, lambda ( ) and kappa (K). There are five main heavy chain classes (or isotypes) which determine the functional activity of an antibody molecule: IgM, IgD, IgG, IgA and IgE.

[0075] Each heavy and light chain contains a constant region (or constant domain) and a variable region (or variable domain). In combination, the heavy and the light chain variable regions specifically bind the antigen.

[0076] References to “Vu” or “VH” refer to the variable region of an antibody heavy chain, including that of an antigen binding fragment, such as Fv, scFv, dsFv or Fab.

[0077] References to “VL” or “VL” refer to the variable domain of an antibody light chain, including that of an Fv, scFv, dsFv or Fab.

[0078] The VH and VL contain a “framework” region interrupted by three hypervariable regions, also called “complementarity-determining regions” or “CDRs” (see, e.g., Kabat et al.,Docket No: T2025-304PCT (069596.00133)Sequences of Proteins of Immunological Interest, 5th ed., NIH Publication No. 91-3242, Public Health Service, National Institutes of Health, U. S. Department of Health and Human Services, 1991). The sequences of the framework regions of different light or heavy chains are relatively conserved within a species. The framework region of an antibody, that is the combined framework regions of the constituent light and heavy chains, serves to position and align the CDRs in three-dimensional space.

[0079] The CDRs are primarily responsible for binding to an epitope of an antigen. The amino acid sequence boundaries of a given CDR can be readily determined using any of a number of well-known schemes, including those described by Kabat et al. (Sequences of Proteins of Immunological Interest, 5th ed., NIH Publication No. 91-3242, Public Health Service, National Institutes of Health, U. S. Department of Health and Human Services, 1991; “Kabat” numbering scheme), Al-Lazikani et al., (“Standard conformations for the canonical structures of immunoglobulins,” J. Mol. Bio., 273(4):927-948, 1997; “Chothia” numbering scheme), and Lefranc et al. (“IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Dev. Comp. Immunol., 27(1):55-77, 2003; “IMGT” numbering scheme). The CDRs of each chain are typically referred to as CDR1, CDR2, and CDR3 (from the N-terminus to C-terminus), and are also typically identified by the chain in which the particular CDR is located. Thus, a Vn CDR3 is the CDR3 from the Vn of the antibody in which it is found, whereas a VL CDR1 is the CDR1 from the VL of the antibody in which it is found. Light chain CDRs are sometimes referred to as LCDR1, LCDR2, and LCDR3. Heavy chain CDRs are sometimes referred to as HCDR1, HCDR2, and HCDR3.

[0080] In some embodiments, a disclosed antibody includes a heterologous constant domain. For example, the antibody includes a constant domain that is different from a native constant domain, such as a constant domain including one or more modifications (such as the “LS” mutations) to increase half-life.

[0081] A “monoclonal antibody” is an antibody obtained from a population of substantially homogeneous antibodies, that is, the individual antibodies comprising the population are identical and / or bind the same epitope, except for possible variant antibodies, for example, containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against differentDocket No: T2025-304PCT (069596.00133)determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein. In some examples monoclonal antibodies are isolated from a subject. Monoclonal antibodies can have conservative amino acid substitutions which have substantially no effect on antigen binding or other immunoglobulin functions. (See, for example, Greenfield (Ed.), Antibodies: A Laboratory Manual, 2nd ed. New York: Cold Spring Harbor Laboratory Press, 2014.)

[0082] The antibody or antigen binding fragment can be a human antibody or fragment thereof. Chimeric antibodies are also provided. The antibody or antigen binding fragment can include any suitable framework region, such as (but not limited to) a human framework region. Alternatively, a heterologous framework region, such as, but not limited to a mouse or monkey framework region, can be included in the heavy or light chain of the antibodies.

[0083] The antibody can be of any isotype. The antibody can be, for example, an IgM or an IgG antibody, such as IgGl, IgG2, IgG3, or IgG4. The class of an antibody that binds to LSR can be switched with another. In one aspect, a nucleic acid molecule encoding VL or VH is isolated such that it does not include any nucleic acid sequences encoding the constant region of the light or heavy chain, respectively. An antibody that binds LSR that was originally IgG may be class switched to an IgM. Class switching can be used to convert one IgG subclass to another, such as from IgGl to IgG2, IgG3, or IgG4.

[0084] A “humanized” antibody or antigen binding fragment includes a human framework region and one or more CDRs from a non-human (such as a mouse, rat, or synthetic) antibody or antigen binding fragment. The non-human antibody or antigen binding fragment providing the CDRs is termed a “donor,” and the human antibody or antigen binding fragment providing the framework is termed an “acceptor.” In some embodiments, all the CDRs are from the donor immunoglobulin in a humanized immunoglobulin. Constant regions need not be present, but ifDocket No: T2025-304PCT (069596.00133)they are, they can be substantially identical to human immunoglobulin constant regions, such as at least about 85-90%, such as about 95% or more identical. Hence, all parts of a humanized antibody or antigen binding fragment, except possibly the CDRs, are substantially identical to corresponding parts of natural human antibody sequences.

[0085] A “chimeric antibody” is an antibody which includes sequences derived from two different antibodies, which typically are of different species. In some examples, a chimeric antibody includes one or more CDRs and / or framework regions from one human antibody and CDRs and / or framework regions from another human antibody.

[0086] A “fully human antibody” or “human antibody” is an antibody which includes sequences from (or derived from) the human genome, and does not include sequence from another species. In some embodiments, a human antibody includes CDRs, framework regions, and (if present) an Fc region from (or derived from) the human genome. Human antibodies can be identified and isolated using technologies for creating antibodies based on sequences derived from the human genome, for example by phage display or using transgenic animals (see, e.g., Barbas et al. Phage display: A Laboratory Manuel. 1st Ed. New York: Cold Spring Harbor Laboratory Press, 2004. Print.; Lonberg, Nat. Biotech., 23: 1117-1125, 2005; Lonenberg, Curr. Opin. Immunol., 20:450-459, 2008).

[0087] Conservative variants: “Conservative” amino acid substitutions are those substitutions that do not substantially affect or decrease a function of a protein, such as the ability of the protein to interact with a target protein. For example, an LSR-specific antibody can include up to 1, 2, 3, 4, 5, 6, 7, 8, 9, or up to 10 conservative substitutions compared to a reference antibody sequence and retain specific binding activity for LSR and / or LSR inhibition. The term conservative variation also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid.

[0088] Individual substitutions, deletions or additions which alter, add or delete a single amino acid or a small percentage of amino acids (in some embodiments less than 5%, in some embodiments less than 1%) in an encoded sequence are conservative variations where the alterations result in the substitution of an amino acid with a chemically similar amino acid.

[0089] The following six groups are examples of amino acids that are considered to be conservative substitutions for one another: 1) Alanine (A), Serine (S), and Threonine (T); 2) Aspartic acid (D) and Glutamic acid (E); 3) Asparagine (N) and Glutamine (Q); 4) Arginine (R)Docket No: T2025-304PCT (069596.00133)and Lysine (K); 5) Tsoleucine (I), Leucine (L), Methionine (M), Valine (V); and 6) Phenylalanine (F), Tyrosine (Y), and Tryptophan (W).

[0090] Non-conservative substitutions are those that reduce an activity or function of the LSR specific antibody, such as the ability to specifically bind to LSR. For instance, if an amino acid residue is essential for a function of the protein, even an otherwise conservative substitution may disrupt that activity. Thus, a conservative substitution does not alter the basic function of a protein of interest.

[0091] Expression: Transcription or translation of a nucleic acid sequence. For example, an encoding nucleic acid sequence (such as a gene) can be expressed when its DNA is transcribed into RNA or an RNA fragment, which in some examples is processed to become mRNA. An encoding nucleic acid sequence (such as a gene) may also be expressed when its mRNA is translated into an amino acid sequence, such as a protein or a protein fragment. In a particular example, a heterologous gene is expressed when it is transcribed into an RNA. In another example, a heterologous gene is expressed when its RNA is translated into an amino acid sequence. Regulation of expression can include controls on transcription, translation, RNA transport and processing, degradation of intermediary molecules such as mRNA, or through activation, inactivation, compartmentalization or degradation of specific protein molecules after they are produced.

[0092] Expression Control Sequences: Nucleic acid sequences that regulate the expression of a heterologous nucleic acid sequence to which it is operatively linked Expression control sequences are operatively linked to a nucleic acid sequence when the expression control sequences control and regulate the transcription and, as appropriate, translation of the nucleic acid sequence. Thus, expression control sequences can include appropriate promoters, enhancers, transcriptional terminators, a start codon (ATG) in front of a protein-encoding gene, splice signals for introns, maintenance of the correct reading frame of that gene to permit proper translation of mRNA and stop codons. The term “control sequences” is intended to include, at a minimum, components whose presence can influence expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences. Expression control sequences can include a promoter.

[0093] Expression vector: A vector comprising a recombinant polynucleotide comprising expression control sequences operatively linked to a nucleotide sequence to be expressed. AnDocket No: T2025-304PCT (069596.00133)expression vector comprises sufficient cis-acting elements for expression; other elements for expression can be supplied by the host cell or in an in vitro expression system. Non-limiting examples of expression vectors include cosmids, plasmids (e.g., naked or contained in liposomes) and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) that incorporate the recombinant polynucleotide.

[0094] A polynucleotide can be inserted into an expression vector that contains a promoter sequence which facilitates the efficient transcription of the inserted genetic sequence of the host. The expression vector typically contains an origin of replication, a promoter, as well as specific nucleic acid sequences that allow phenotypic selection of the transformed cells.

[0095] Fc region: The constant region of an antibody excluding the first heavy chain constant domain. Fc region generally refers to the last two heavy chain constant domains of IgA, IgD, and IgG, and the last three heavy chain constant domains of IgE and IgM. An Fc region may also include part or all of the flexible hinge N-terminal to these domains. For IgA and IgM, an Fc region may or may not include the tailpiece, and may or may not be bound by the J chain. For IgG, the Fc region is typically understood to include immunoglobulin domains Cy2 and Cy3 and optionally the lower part of the hinge between Cyl and Cy2. Although the boundaries of the Fc region may vary, the human IgG heavy chain Fc region is usually defined to include residues following C226 or P230 to the Fc carboxyl-terminus, wherein the numbering is according to Kabat. For IgA, the Fc region includes immunoglobulin domains Ca2 and Ca3 and optionally the lower part of the hinge between Cal and Ca2.

[0096] Fragments. Antigen binding fragments are encompassed by the present disclosure, such as Fab, F(ab')2, and Fv which include a heavy chain (VH) and light chain (VL) and bind to or inhibit LSR. These antibody fragments retain the ability to selectively bind with the antigen and are “antigen-binding” fragments. Non-limiting examples of such fragments include: (1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule, can be produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain; (2) Fab', the fragment of an antibody molecule can be obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; (3) (Fab')2, the fragment of the antibody that can be obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; F(ab')2 is a dimer of two Fab' fragments held together by two disulfide bonds; (4) Fv, aDocket No: T2025-304PCT (069596.00133)genetically engineered fragment containing the VL and VL expressed as two chains; and(5) Single chain antibody (such as scFv), defined as a genetically engineered molecule containing the VH and the VL linked by a suitable polypeptide linker as a genetically fused single chain molecule (see, e.g., Ahmad et al., Clin. Dev. Immunol., 2012, doi:10.1155 / 2012 / 980250; Marbry and Snavely, IDrugs, 13(8):543-549, 2010). (6) A dimer of a single chain antibody (scFV2), defined as a dimer of a scFV. This has also been termed a “miniantibody.”

[0097] Any suitable method of producing the above-discussed antigen binding fragments may be used. Non-limiting examples are provided in Harlow and Lane, Antibodies: A Laboratory Manual, 2nd, Cold Spring Harbor Laboratory, New York, 2013. Antigen binding fragments can be prepared by proteolytic hydrolysis of the antibody or by expression in a host cell (such as an E. coli cell) of DNA encoding the fragment. Antigen binding fragments can also be obtained by pepsin or papain digestion of whole antibodies by conventional methods. Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent lightheavy chain fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.

[0098] Host cell: Cells in which a vector can be propagated and its DNA expressed. The cell may be prokaryotic or eukaryotic. The term also includes any progeny of the subject host cell. It is understood that all progeny may not be identical to the parental cell since there may be mutations that occur during replication. However, such progeny are included when the term “host cell” is used.

[0099] IgA: A polypeptide belonging to the class of antibodies that are substantially encoded by a recognized immunoglobulin alpha gene. In humans, this class or isotype comprises IgAl and IgA2. IgA antibodies can exist as monomers, polymers (referred to as plgA) of predominantly dimeric form, and secretory IgA. The constant chain of wild-type IgA contains an 18-amino-acid extension at its C-terminus called the tail piece (tp). Polymeric IgA is secreted by plasma cells with a 15-kDa peptide called the J chain linking two monomers of IgA through the conserved cysteine residue in the tail piece.

[0100] IgG: A polypeptide belonging to the class or isotype of antibodies that are substantially encoded by a recognized immunoglobulin gamma gene. In humans, this class comprises IgGl, IgG2, IgG3, and IgG4.Docket No: T2025-304PCT (069596.00133)

[0101] Nucleic acid (molecule or sequence): A deoxyribonucleotide or ribonucleotide polymer or combination thereof including without limitation, cDNA, mRNA, genomic DNA, and synthetic (such as chemically synthesized) DNA or RNA. The nucleic acid can be double stranded (ds) or single stranded (ss). Where single stranded, the nucleic acid can be the sense strand or the antisense strand. Nucleic acids can include natural nucleotides (such as A, T / U, C, and G), and can include analogs of natural nucleotides, such as labeled nucleotides.

[0102] “ cDNA” refers to a DNA that is complementary or identical to an mRNA, in either single stranded or double stranded form.

[0103] “Encoding” refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (i.e., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom. Thus, a gene encodes a protein if transcription and translation of mRNA produced by that gene produces the protein in a cell or other biological system. Both the coding strand, the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings, and non-coding strand, used as the template for transcription, of a gene or cDNA can be referred to as encoding the protein or other product of that gene or cDNA. Unless otherwise specified, a “nucleotide sequence encoding an amino acid sequence” includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. Nucleotide sequences that encode proteins and RNA may include introns.

[0104] Pharmaceutically acceptable carriers: The pharmaceutically acceptable carriers of use are conventional. Remington: The Science and Practice of Pharmacy, 22nd ed., London, UK: Pharmaceutical Press, 2013, describes compositions and formulations suitable for pharmaceutical delivery of the disclosed agents. In general, the nature of the carrier will depend on the particular mode of administration being employed. For instance, parenteral formulations usually include injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle. For solid compositions (e.g., powder, pill, tablet, or capsule forms), conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate. In addition to biologically neutral carriers,Docket No: T2025-304PCT (069596.00133)pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, added preservatives (such as nonnatural preservatives), and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate. In particular examples, the pharmaceutically acceptable carrier is sterile and suitable for parenteral administration to a subject for example, by injection. In some embodiments, the active agent and pharmaceutically acceptable carrier are provided in a unit dosage form such as a pill or in a selected quantity in a vial. Unit dosage forms can include one dosage or multiple dosages (for example, in a vial from which metered dosages of the agents can selectively be dispensed).

[0105] Polypeptide: A polymer in which the monomers are amino acid residues that are joined together through amide bonds. When the amino acids are alpha-amino acids, either the L-optical isomer or the D-optical isomer can be used, the L-isomers being preferred. The terms “polypeptide” or “protein” as used herein are intended to encompass any amino acid sequence and include modified sequences such as glycoproteins. A polypeptide includes both naturally occurring proteins, as well as those that are recombinantly or synthetically produced. A polypeptide has an amino terminal (N-terminal) end and a carboxy-terminal end. In some embodiments, the polypeptide is a disclosed antibody or a fragment thereof.

[0106] Purified: The term purified does not require absolute purity; rather, it is intended as a relative term. Thus, for example, a purified peptide preparation is one in which the peptide or protein (such as an antibody) is more enriched than the peptide or protein is in its natural environment within a cell. In some embodiments, a preparation is purified such that the protein or peptide represents at least 50% of the total peptide or protein content of the preparation.

[0107] Recombinant: A recombinant nucleic acid is one that has a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination can be accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, for example, by genetic engineering techniques. A recombinant protein is one that has a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. In several embodiments, a recombinant protein is encoded by a heterologous (for example, recombinant) nucleic acid that has been introduced into a host cell, such as a bacterial or eukaryotic cell. The nucleic acid canDocket No: T2025-304PCT (069596.00133)be introduced, for example, on an expression vector having signals capable of expressing the protein encoded by the introduced nucleic acid or the nucleic acid can be integrated into the host cell chromosome.

[0108] Sequence identity: The identity between two or more nucleic acid sequences, or two or more amino acid sequences, is expressed in terms of the identity between the sequences. Sequence identity can be measured in terms of percentage identity; the higher the percentage, the more identical the sequences. Homologs and variants of a VL or a Vu of an antibody that specifically binds a target antigen are typically characterized by possession of at least about 75% sequence identity, for example at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity counted over the full-length alignment with the amino acid sequence of interest. Generally, once two sequences are aligned, the number of matches is determined by counting the number of positions where an identical nucleotide or amino acid residue is present in both sequences. The percent sequence identity between the two sequences is determined by dividing the number of matches either by the length of the sequence set forth in the identified sequence, or by an articulated length (such as 100 consecutive nucleotides or amino acid residues from a sequence set forth in an identified sequence), followed by multiplying the resulting value by 100.

[0109] Vector: An entity containing a nucleic acid molecule (such as a DNA or RNA molecule) bearing a promoter(s) that is operationally linked to the coding sequence of a protein of interest and can express the coding sequence. Non-limiting examples include a naked or packaged (lipid and / or protein) DNA, a naked or packaged RNA, a subcomponent of a virus or bacterium or other microorganism that may be replication-incompetent, or a virus or bacterium or other microorganism that may be replication-competent. A vector is sometimes referred to as a construct. Recombinant DNA vectors are vectors having recombinant DNA. A vector can include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication. A vector can also include one or more selectable marker genes and other genetic elements.I. Monoclonal Antibodies, Antigen Binding Fragments, Nucleic Acids

[0110] This disclosure provides monoclonal antibodies and antigen binding fragments, which in some embodiments are directed against LSR.Docket No: T2025-304PCT (069596.00133)

[0111] In one aspect, provided herein is an isolated monoclonal antibody, comprising: a heavy chain variable region (VH); and a light chain variable region (VL); wherein the VH comprises a first heavy chain complementarity determining region (HCDR1), a second heavy chain complementarity determining region (HCDR2), and a third heavy chain complementarity determining region (HCDR3); wherein the VL comprises a first light chain complementarity determining region (LCDR1), a second light chain complementarity determining region (LCDR2), and a third light chain complementarity determining region (LCDR3); and wherein (a) HCDR1 comprises a sequence with at least 80% identity to SEQ ID NO: 3, HCDR2 comprises a sequence with at least 80% identity to SEQ ID NO: 4, and HCDR3 comprises a sequence with at least 80% identity to SEQ ID NO: 5, and / or (b) LCDR1 comprises a sequence with at least 80% identity to SEQ ID NO: 10, LCDR2 comprises the amino acid sequence YTS, and LCDR3 comprises a sequence with at least 80% identity to SEQ ID NO: 12.

[0112] In some embodiments, (i) HCDR1 comprises an amino acid sequence with at least 85%, at least 90%, or at least 95% identity to SEQ ID NO: 3; HCDR2 comprises an amino acid sequence with at least 85%, at least 90%, or at least 95% identity to SEQ ID NO: 4, and HCDR3 comprises an amino acid sequence with at least 85%, at least 90%, or at least 95% identity to SEQ ID NO: 5, and / or (ii) LCDR1 comprises an amino acid sequence with at least 85%, at least 90%, or at least 95% identity to SEQ ID NO: 10; and LCDR3 comprises an amino acid sequence with at least 85%, at least 90%, or at least 95% identity to SEQ ID NO: 12; optionally LCDR2 comprises the amino acid sequence YTS.

[0113] In some embodiments of any monoclonal antibody disclosed herein, HCDR1 comprises the sequence set forth as SEQ ID NO: 3. In other embodiments of any monoclonal antibody disclosed herein, HCDR2 comprises the sequence set forth as SEQ ID NO: 4. In other embodiments of any monoclonal antibody disclosed herein, HCDR3 comprises the sequence set forth as SEQ ID NO: 5. In other embodiments of any monoclonal antibody disclosed herein, LCDR1 comprises the sequence set forth as SEQ ID NO: 10. In other embodiments, LCDR2 comprises the amino acid sequence YTS. In other embodiments of any monoclonal antibody disclosed herein, LCDR3 comprises the sequence set forth as SEQ ID NO: 12.

[0114] In some embodiments, (a) HCDR1 comprises the sequence set forth as SEQ ID NO: 3, HCDR2 comprises the sequence set forth as SEQ ID NO: 4, and HCDR3 comprises the sequence set forth as SEQ ID NO: 5, and / or (b) LCDR1 comprises the sequence set forth as SEQDocket No: T2025-304PCT (069596.00133)ID NO: 10 and LCDR3 comprises the sequence set forth as SEQ ID NO: 12, optionally LCDR2 comprises the amino acid sequence YTS.

[0115] In some embodiments of any monoclonal antibody disclosed herein, the VH comprises a sequence at least 80%, at least 85%, at least 90%, or at least 95% identical to the sequence set forth as SEQ ID NO: 1; and / or the VL comprises a sequence at least 80%, at least 85%, at least 90%, or at least 95% identical to the sequence set forth as SEQ ID NO: 8. In other embodiments of any monoclonal antibody disclosed herein,, the VH comprises the sequence set forth as SEQ ID NO: 1; and / or the VL comprises the sequence set forth as SEQ ID NO: 8.

[0116] In still other embodiments of any monoclonal antibody disclosed herein, the antibody comprises (i) a human framework region and / or (ii) a human constant domain.

[0117] In some embodiments, the VH constant region comprises the sequence at least 80%, at least 85%, at least 90%, or at least 95% identical to the sequence set forth as SEQ ID NO: 2; and / or the VL constant region comprises the sequence at least 80%, at least 85%, at least 90%, or at least 95% identical to the sequence set forth as SEQ ID NO: 9. In still other embodiments, the VH constant region comprises the sequence set forth as SEQ ID NO: 2; and / or the VL constant region comprises the sequence set forth as SEQ ID NO: 9. In other embodiments, the antibody is a human antibody.

[0118] In some variations of any aspect or embodiment, the antibody or antibody fragment disclosed herein binds to Lipolysis-Stimulated Lipoprotein Receptor (LSR).

[0119] In another aspect, an isolated nucleic acid molecule encoding any disclosed antibody or antigen binding fragment is provided herein. In some embodiments, the isolated nucleic acid molecule comprises (a) a DNA sequence at least 80%, at least 85%, at least 90%, or at least 95% identical to the sequence set forth as SEQ ID NO: 6 and / or (b) a DNA sequence at least 80%, at least 85%, at least 90%, or at least 95% identical to the sequence set forth as the amino acid sequence set forth as SEQ ID NO: 13. In other embodiments, the isolated nucleic acid molecule comprises (a) a DNA sequence set forth as SEQ ID NO: 6 and / or (b) a DNA sequence set forth as SEQ ID NO: 13.

[0120] In one aspect, the present application discloses an isolated antigen binding fragment of the antibody disclosed herein, wherein the antigen binding fragment comprises any variation of HCDR1, HCDR2, and HCDR3; and / or LCDR1, LCDR2, and LCDR3; and / or the VH and / or the VL of the antibody as disclosed herein, for example, one or more of the sequences ofDocket No: T2025-304PCT (069596.00133)HCDR1, HCDR2, HCDR3; LCDR1, LCDR2, and / or LCDR3 disclosed herein or one or both of the VH and the VL sequences disclosed herein.

[0121] The present disclosure also provides an isolated nucleic acid molecule encoding each monoclonal antibody or antigen binding fragment thereof as disclosed herein. In some embodiments, the nucleic acid molecule is a recombinant nucleic acid molecule. In some embodiments, the nucleic acid molecule comprises a cDNA sequence encoding the antibody or antigen binding fragment. In some embodiments, the nucleic acid molecule comprises an RNA molecule encoding the antibody or antigen binding fragment. In some embodiments, the nucleic acid molecule further comprises a promoter.

[0122] The present disclosure also provides an expression vector comprising a nucleic acid molecule as disclosed herein, or a host cell comprising such a nucleic acid molecule or an expression vector.

[0123] Disclosed herein are LSR binding monoclonal antibodies. The anti-LSR monoclonal antibodies may include a human, chimeric, or humanized anti-LSR antibody or fragment thereof. For example, a binding molecule may contain the CDRs of the light and heavy chain variable regions of a murine anti-LSR antibody. A humanized anti-LSR antibody or fragment may include the complementarity-determining regions (CDRs) of murine anti-LSR and human antibody constant and framework (FR) region sequences, which may be substituted with at least one amino acid from corresponding FRs of a murine antibody. An antibody or fragment may include a humanized IgGl.

[0124] An anti-LSR monoclonal antibody may be a chimeric anti-LSR antibody or fragment thereof and may include the light and heavy chain variable regions of a murine anti-LSR antibody, attached to human antibody constant regions. A chimeric antibody or fragment thereof may include a chimeric IgGl or fragment thereof.

[0125] The anti-LSR antibody may also include a fragment which includes a F(ab')2, Fab, scFv, Fv, or a fusion protein utilizing part or all of the light and heavy chains of the F(ab')2, Fab, scFv, or Fv, such that the fragment is capable of binding to LSR. The binding molecule may be selected or designed to be multivalent, or multivalent and multispecific. The fragments may form a bispecific binding molecule or a diabody. In some embodiments, the binding molecule includes a fusion protein that includes four or more Fvs, or Fab's of the antibodies or fragments thereof. In a further embodiment, the binding molecule includes a fusion protein that includes one or moreDocket No: T2025-304PCT (069596.00133)Fvs or Fab's of an anti- LSR antibody or fragment thereof, and one or more Fvs or Fab's from an antibody specific for a tumor cell marker that is not an LSR antigen. The anti- LSR antibody may include human constant regions of IgGl, IgG2a, IgG3, or IgG4.II. Antibody Drug Conjugates and Dual Antibody Drug Conjugates

[0126] In one aspect, provided herein is an antibody-drug conjugate comprising a disclosed monoclonal antibody conjugated to a first pharmaceutically active agent via a first bivalent linker. Any pharmaceutically active agent not inconsistent with the technical objectives of the current disclosure can be used.

[0127] In some embodiments, the first pharmaceutically active agent is a chemotherapeutic agent. In some embodiments, the first pharmaceutically active agent is selected from monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), emtansine (or mertansine (DM1)), Dxd (Exatecan derivative), SN-38, pyrrolobenzodiazepine dimer (PBD dimer, GD-1882), calicheamicin, spliceostatin A and combinations thereof.

[0128] In another aspect, the present disclosure provides an antigen binding fragment-drug conjugate comprising any antigen binding fragment bound to at least one pharmaceutically active agent, such as a chemotherapeutic agent.

[0129] In one embodiment, the monoclonal antibody is conjugated to a second pharmaceutically active agent via a second bivalent linker (referred to herein as a dual antibodydrug conjugate or dual ADC). Any pharmaceutically active agent not inconsistent with the technical objectives of the current disclosure can be used. In some variations, the second pharmaceutically active agent is a chemotherapeutic agent. In some variations, the second pharmaceutically active agent is an immunotherapy agent.

[0130] The present disclosure further provides a dual antibody drug conjugate comprising an anti-LSR antibody conjugated to a chemotherapeutic agent via a first bivalent linker and an immunotherapy agent via a second bivalent linker.

[0131] In some embodiments of any antibody drug conjugate or dual antibody drug conjugate, the chemotherapeutic agent is selected from the group of alkylating agents, platinum based agents, antibiotics / anthracyclines, anti-metabolites and combinations thereof. In some embodiments, the chemotherapeutic agent is selected from altretamine, bendamustine, busulfan, carmustine, chlorambucil, cyclophosphamide, dacarbazine, ifosfamide, lomustine, lurbinectedin,Docket No: T2025-304PCT (069596.00133)mechlorethamine, melphalan, procarbazine, streptozocin, temozolomide, thiotepa, trabectedin, carboplatin, cisplatin, oxaliplatin, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, mitomycin, mitoxantrone, plicamycin, valrubicin, methotrexate, pemetrexed, pralatrexate, trimetrexate, azathioprine, cladribine, fludarabine, mercaptopurine, thioguanine, azacitidine, capecitabine, cytarabine, decitabine, floxuridine, fluorouracil, gemcitabine, trifluridine / tipracil, romidepsin, vorinostat and combinations thereof.

[0132] In some embodiments of any antibody drug conjugate or dual antibody drug conjugate, the chemotherapeutic agent is a topoisomerase 1 inhibitor, aDNA damaging reagent or a spliceosome inhibitor. In some embodiments, the chemotherapeutic is monomethyl auri statin E (MMAE), monomethyl auri statin F (MMAF), emtansine (or mertansine (DM1)), Dxd (Exatecan derivative), SN-38, pyrrolobenzodiazepine dimer (PBD dimer, GD-1882), calicheamicin, spliceostatin A. In some embodiments, the topoisomerase 1 inhibitor is Dxd or SN-38. In some embodiments, the DNA damaging reagent is PBD dimer or calicheamicin. In other embodiments, the spliceosome inhibitor is spliceostatin A.

[0133] In some embodiments, the immunotherapy agent of any antibody drug conjugate or dual antibody drug conjugate is selected from the group of immune checkpoint inhibitors, T-cell transfer therapies, immune system modulators and combinations thereof. In some embodiments, the immunotherapy agent is a toll-like receptor 7 / 8 (TLR 7 / 8) agonist. In certain examples, the TLR 7 / 8 agonist comprises an imidazoquinoline, such as TLR7 / 8 Agonist 1 (IMQ herein), gardiquimod (l-(4-amino-2-((ethylamino)methyl)-lH-imidazo[4,5-c]quinolin-l-yl)-2-methylpropan-2-ol), resiquimod (R848), imiquimod (l-isobutyl-lH-imidazo[4,5-c]quinolin-4-amine) or combinations thereof. TLR7 / 8 Agonist 1 (IMQ) has the chemical namel-(4-aminomethylbenzyl)-2-butyl-lH-imidazo[4,5-c]quinolin-4-amine; when the -NEE group is substituted with an -SH group, as in the synthesis of the Dual ADC, it is referred to as IMQ* herein. The chemical name of resiquimod is l-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-l-yl]-2-methylpropan-2-ol) and when the -OH group is replaced with an -NH2 group, it is designated R848*. In some embodiments, the immune checkpoint inhibitor is a PD-1 / PD-L1 inhibitor.

[0134] Consistent with terms of art, the bivalent linker disclosed herein linking a monoclonal antibody or fragment thereof to a pharmaceutically active agent in a conjugate, such as ADC or dual-ADC is typically characterized by the chemical starting materials, intermediates or chemicalDocket No: T2025-304PCT (069596.00133)reactions used in preparation of such a linker. For example, a dibromomaleimide-containing bivalent linker (“DBM linker”) is understood to not contain the chemical moiety dibromomaleimide, but instead to result from a chemical reaction in which dibromomaleimide is a starting material or intermediate in the synthetic pathway of the conjugate, as shown herein. Alternately, a DBM linker can also refer to a linker containing a maleimido moiety that does not and did not contain a bromine moiety. In such an example, a maleimido moiety on a linker is reacted directly with cysteine residues of an antibody, in which the disulfide bond is broken using, for example, tris(2-carboxyethyl)-phosphine (TCEP). A linker referred herein as a DBM linker thus contains a maleimido moiety. Most typically a DBM linker’s maleimido moiety binds via two thioether bonds to the monoclonal antibody, while the other ‘end’ of the linker binds to a pharmaceutically active agent, such as a chemotherapeutic agent or immunotherapy agent disclosed herein. Similarly, a phosphine-azide linker does not contain a phosphine-azide moiety, but instead the bivalent linker conjugated to the antibody and a pharmaceutically active agent or drug results from a phosphine azide reaction.

[0135] According to such designations, a bivalent linker disclosed herein can comprise a phosphine azide linker, a N-succinimidyl S-acetylthioacetate sulfo-succinimidyl-4-(A-maleimidomethyl)-cyclohexane-l -carboxylate (SATA sulfo-SMCC) linker, a sulfo-succinimidyl-4-(A-maleimidomethyl)-cyclohexane-l-carboxylate (sulfo-SMCC) linker, or a dibromomaleimide (DBM) linker. Examples of DBM linkers include but are not limited to mal eimide, DBM-GGFG (referred to as DBM-Gly-Gly-Phe-Gly), DBM-GGG, DMB-Gly-Gly-Phe-Gly-PAB-OH, DBM-Val-Cit-PABC-PNP (where Vai = valine; Cit = citrulline; PABC = p-aminobenzyl; PNP = p-nitrophenyl), or DBM-Val-Cit-PAB (also DBM-VC-PAB), an example of which is MC-VC-PAB, where MC is maleimidocaproyl.

[0136] Typically, a phosphine-azide linker comprises two amide moieties, the first of which binds to a drug and the second of which binds to the monoclonal antibody (e.g. mAb-NH-C(O)-..,-C(O)-NH-drug, where -... - comprises at least a phosphine moiety, most commonly a triphenylphosphine moiety).

[0137] Typically, a maleimide containing linker, or DBM linker, comprises a maleimide moiety bound via sulfur bond(s) to the mAb and an amide moiety bound to the drug. Generally, the mAb is bound via two sulfur bonds to the maleimide moiety, as shown in the Figures.Docket No: T2025-304PCT (069596.00133)

[0138] The sulfo-SMCC linker disclosed herein comprises an amide moiety and a sulfur bound to the maleimide moiety; generally the amide moiety binds to the antibody and the sulfur to the drug (e.g. mAb-NH-C(O)-...maleimide-S-drug). When a sulfo-SMCC linker is modified by SATA, the resulting linker comprises two amide moieties, the first of which can bind to the mAb and the second of which can bind to the drug (e g. mAb-NH-C(O)-... -C(O)-NH-drug).

[0139] In some embodiments, the pharmaceutically active agent in a conjugate disclosed herein is a chemotherapeutic agent, such as an anti-tumor cancer agent; in another variation, the pharmaceutically active agent is a tubulin inhibitor, in yet another variation, the pharmaceutically active agent is mertansine. In another variation, the linker is a Sulfo-SMCC linker.III. Compositions

[0140] In another aspect, a pharmaceutical composition is provided herein, comprising an effective amount of any monoclonal antibody or any antigen binding fragment disclosed herein including in Section I; and a pharmaceutically acceptable carrier.

[0141] In another aspect, disclosed herein is a pharmaceutical composition comprising any antibody-drug conjugate, including any dual antibody-drug conjugate disclosed herein, including the disclosure of Section II, and a pharmaceutically acceptable carrier.

[0142] In general, an antibody / antigen binding fragment or conjugate described herein is mixed with a suitable carrier or excipient in a therapeutically effective amount. By a “therapeutically effective dose”, “therapeutically effective amount”, or, interchangeably, “pharmacologically acceptable dose” or “pharmacologically acceptable amount”, it is meant that a sufficient amount of the antibody / antigen binding fragment or conjugate and a pharmaceutically acceptable carrier, will be present in order to achieve a desired result, e.g., treating a disease, such as cancer, expressing LSR (as further described herein).

[0143] The present disclosure further provides a pharmaceutical composition comprising (a) an antibody or an antigen binding fragment of Section I or a conjugate of Section II; (b) a pharmaceutically active agent; and (c) a pharmaceutically acceptable carrier. Any pharmaceutically active agent not inconsistent with the technical objectives of the current disclosure can be used. In some embodiments, the pharmaceutically active agent is a chemotherapeutic agent. In some embodiments, the pharmaceutically active agent is an immunotherapy agent.Docket No: T2025-304PCT (069596.00133)

[0144] In some embodiments, the chemotherapeutic agent is selected from the group of alkylating agents, platinum based agents, antibiotics / anthracyclines, anti-metabolites and combinations thereof. In some embodiments, the chemotherapeutic agent is selected from altretamine, bendamustine, busulfan, carmustine, chlorambucil, cyclophosphamide, dacarbazine, ifosfamide, lomustine, lurbinectedin, mechlorethamine, melphalan, procarbazine, streptozocin, temozolomide, thiotepa, trabectedin, carboplatin, cisplatin, oxaliplatin, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, mitomycin, mitoxantrone, plicamycin, valrubicin, methotrexate, pemetrexed, pralatrexate, trimetrexate, azathioprine, cladribine, fludarabine, mercaptopurine, thioguanine, azacitidine, capecitabine, cytarabine, decitabine, floxuridine, fluorouracil, gemcitabine, trifluridine / tipracil, romidepsin, vorinostat and combinations thereof.

[0145] In some embodiments, the chemotherapeutic agent is a topoisomerase 1 inhibitor, a DNA damaging reagent or a spliceosome inhibitor. In some embodiments, the chemotherapeutic is monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), emtansine (or mertansine (DM1)), Dxd (Exatecan derivative), SN-38, pyrrolobenzodiazepine dimer (PBD dimer, GD-1882), calicheamicin, spliceostatin A. In some embodiments, the topoisomerase 1 inhibitor is Dxd or SN-38. In some embodiments, the DNA damaging reagent is PBD dimer or calicheamicin. In other embodiments, the spliceosome inhibitor is spliceostatin A.

[0146] In some embodiments, the immunotherapy agent is selected from the group of immune checkpoint inhibitors, T-cell transfer therapies, immune system modulators and combinations thereof. In some embodiments, the immunotherapy agent is a toll-like receptor 7 / 8 (TLR 7 / 8) agonist. In certain examples, the TLR 7 / 8 agonist comprises an imidazoquinoline, such as TLR7 / 8 Agonist 1 (IMQ), IMQ*, gardiquimod, resiquimod, R848*, or combinations thereof. In some embodiments, the immune checkpoint inhibitor is a PD-1 / PD-L1 inhibitor.

[0147] In some embodiments, the immunotherapy agent comprises a monoclonal antibody. In some embodiments, the immunotherapy agent comprises trastuzumab, amivantamab, atezolizumab, avelumab, bevacizumab, blinatumomab, cemiplimab, cetuximab, daratumumab, dostarlimab, durvalumab, elotuzumab, epcoritamab, gemtuzumab, glofitamab, ibritumomab tioxetan, ipilimumab, isatuximab, margetuximab, mogamulizumab, mosunetuzumab, naxitamamb, necitumumab, nivolumab, nivolumab and relatlimab, obinutuzumab, ofatumumab,Docket No: T2025-304PCT (069596.00133)panitumumab, pembrolizumab, pertuzumab, ramucirumab, retifanlimab, rituximab, siltuximab, tafasitamamb, talquetamab, tebentafusp, teclistamab, tremelimumab or combinations thereof.

[0148] In another embodiment, the immunotherapy comprises a cell therapy, such as CAR-T, gene therapy, immunotherapy, etc. In some embodiments, the immunotherapy is selected from the group of brexucabtagene autoleucel, axicabtagene ciloleucel, ciltacabtagene, idecabtagene vicleucel, lisocabtagene maraleucel, tisagenlecleucel, nadofaragene firadenovec, sipuleucel-t, talimogene laherparepvec, tagraxofusp or combinations thereof.

[0149] In general, the antibody / antigen binding fragment or conjugate, as well as compositions comprising such an antibody / antigen binding fragment or conjugate as described herein, are administered in a therapeutically effective amount by any of the accepted modes of administration. The actual amount of the antibody / antigen binding fragment and / or conjugate depends upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the antibody / antigen binding fragment and / or conjugate used, the route and form of administration, and other factors. The antibody / antigen binding fragment and / or conjugate can be administered according to any suitable dosage regimes, such as once, twice, three times, or four times, etc. a day, or as needed. All of these factors are within the skill of the attending clinician. In some embodiments, the antibody / antigen binding fragment, composition and / or conjugate is administered one or more times during a treatment cycle. In further embodiments, the treatment cycle is 21 days. In other embodiments, the treatment cycle is 28 days. In some embodiments, the antibody / antigen binding fragment, composition and / or conjugate is administered one or more times during a treatment cycle for up to four treatment cycles.

[0150] Therapeutically effective amounts of the antibody / antigen binding fragment and / or conjugate may range from approximately 0.03 to 50 mg per kilogram body weight of the recipient per day; for example, about 0.1-25 mg / kg / day, or from about 0.5 to 10 mg / kg / day. Thus, for administration to a 70 kg person, the dosage range can be about 1-3,500 mg per day.

[0151] In some of the embodiments of the technology described herein, the pharmaceutical compositions are packaged in unit dosage form. The unit dosage form is effective in treating a disease and / or disorder. Generally, a unit dosage including an antibody / antigen binding fragment and / or conjugate of the present technology will vary depending on patient considerations. Such considerations include, for example, age, protocol, condition, sex, extent of disease,Docket No: T2025-304PCT (069596.00133)contraindications, concomitant therapies, and the like. An exemplary unit dosage based on these considerations can also be adjusted or modified by a physician skilled in the art. For example, a unit dosage for a patient comprising an antibody / antigen binding fragment and / or conjugate of the present technology can vary from 3 x 10'5g / kg to 1 g / kg, preferably, l x 10'3g / kg to 1.0 g / kg. Dosage of the present technology can also vary from 0.01 mg / kg to 100 mg / kg or, preferably, from 0.1 mg / kg to 10 mg / kg.

[0152] In some embodiments, the unit dosage comprises 0.01 mg / kg to 0.5 g / kg. In some embodiments, the unit dosage comprises 0.01 mg / kg to 100 mg / kg. In some embodiments, the unit dosage comprises 0.01 mg / kg to 50 mg / kg. In some embodiments, the unit dosage comprises 0.01 mg / kg to 10 mg / kg. In some embodiments, the unit dosage comprises 0.01 mg / kg to 5 mg / kg. In some embodiments, the unit dosage comprises 0.1 mg / kg to 0.5 g / kg. In some embodiments, the unit dosage comprises 0.1 mg / kg to 100 mg / kg. In some embodiments, the unit dosage comprises 0.1 mg / kg to 50 mg / kg. In some embodiments, the unit dosage comprises 0.01 mg / kg to 10 mg / kg. In some embodiments, the unit dosage comprises 0.1 mg / kg to 5 mg / kg.

[0153] In general, the antibody / antigen binding fragment and / or conjugate described herein will be administered as pharmaceutical compositions by any one of the following routes: oral, transdermal, intranasal, by suppository, parenteral (e.g. intramuscular, intravenous or subcutaneous), or intrathecal administration. Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions. The choice of formulation depends on various factors such as the mode of drug administration and bioavailability of the drug substance.

[0154] In some embodiments, pharmaceutical compositions described herein are comprised of, in general, an antibody / antigen binding fragment and / or conjugate described herein in combination with at least one pharmaceutically acceptable excipient. A pharmaceutical composition described herein may be made in any manner not inconsistent with the technical objectives of the current disclosure. In some instances, acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit. Such excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art. Solid pharmaceutical excipients include but are not limited to starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skimDocket No: T2025-304PCT (069596.00133)milk, and the like. Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc. Preferred liquid carriers, particularly for injectable solutions, include water, saline, phosphate buffered saline, citrate buffer, aqueous dextrose, glycols, etc.

[0155] The amount of an antibody, antigen binding fragment or conjugate described herein in a pharmaceutical formulation or composition can vary within the full range employed by those skilled in the art. In some embodiments, the formulation will contain from about 0.01-99.99 wt.% of the antibody, antigen binding fragment and / or conjugate based on the total weight of the formulation, with the balance being one or more suitable pharmaceutical excipients. Preferably, in some instances, the antibody, antigen binding fragment and / or conjugate described herein is present at a level of about 1-80 wt.%.IV. Methods of Use

[0156] The monoclonal antibodies (mAbs), antigen binding fragments, and conjugates, including antibody-drug conjugates (ADCs) and dual antibody-drug conjugates (dual ADCs) disclosed herein can be used to treat various diseases, including cancer, while minimizing adverse effects on the healthy tissues in patients. ADCs and dual ADCs can carry highly potent drugs and specifically target cancer cells in vivo to deliver pharmaceutically active agents, such as but not limited to, chemotherapeutics. The mAb component of the conjugates disclosed herein, such as in Section I, can also trigger antibody-dependent cell-mediated cytotoxicity, further enhancing their anti-cancer effect. By combining improved anti-cancer efficacy with reduced adverse effects, ADCs and dual ADCs offer advantages over individual administration of mAbs and chemotherapy.

[0157] In one aspect, methods described herein pertain to a therapeutic approach for the treatment of a condition, such as cancer, in a patient or subject in need thereof, particularly a human subject. In some embodiments, the cancer expresses or overexpresses LSR. In some embodiments, the cancer is endometrial cancer, gastric cancer, epithelial cancer, including but not limited to epithelial ovarian cancer, or breast cancer, including but not limited to triple negative breast cancer (TNBC). In some cases, the cancer is TNBC; in other cases, the cancer is epithelial ovarian cancer.Docket No: T2025-304PCT (069596.00133)

[0158] In some aspects, disclosed herein is a method of treating a disease susceptible to LSR inhibition comprising administering an antibody or antigen binding fragment thereof as disclosed herein, such as Section I, or a composition comprising such an antibody or antigen binding fragment, such as disclosed in Section III, to a patient in need thereof.

[0159] In other aspects, disclosed herein is a method of treating a disease susceptible to LSR inhibition comprising administering an ADC or dual ADC disclosed herein, such as in Section II, or administering a composition comprising such conjugates as disclosed herein, such as in Section III.

[0160] In still other aspects, disclosed herein is a method for treating cancer in a subject in need thereof comprising disposing an antibody or antigen binding fragment as disclosed in Section I or an ADC or dual ADC disclosed in Section II or a composition disclosed in Section III within a biological compartment of the subject.

[0161] In some embodiments, an antibody, antigen binding fragment, antibody-drug conjugate, or dual antibody-drug conjugate disclosed herein is administered to the subject in need thereof in combination with one or more pharmaceutically active agents. Any pharmaceutically active agent not inconsistent with the technical objectives of the current disclosure can be used. In some embodiments, the pharmaceutically active agent is a chemotherapeutic as disclosed herein. In some embodiments, the pharmaceutically active agent is an immunotherapy agent as disclosed herein.

[0162] When a combination therapy is used, the one or more pharmaceutically active agents may be administered sequentially or simultaneously with the antibody, antigen binding fragment and / or conjugate described herein. In some embodiments, the one or more additional pharmaceutically active agents is administered prior to the administration of an antibody, antigen binding fragment or conjugate described herein. In some embodiments, the one or more pharmaceutically active agents is administered after the administration of an antibody, antigen binding fragment or conjugate described herein. In some embodiments, the one or more pharmaceutically active agents is administered concurrently with the administration of an antibody, antigen binding fragment or conjugate described herein.

[0163] A combination therapy comprising an antibody, antigen binding fragment or conjugate disclosed herein and one or more additional therapeutic agents may be made in any manner not inconsistent with the technical objectives of the current disclosure.Docket No: T2025-304PCT (069596.00133)

[0164] Moreover, in some embodiments, an antibody, antigen binding fragment or conjugate disclosed herein may be used with different types of therapies. For example, in some cases, an antibody, antigen binding fragment or conjugate disclosed herein is used in combination with radiotherapy. In other cases, an antibody, antigen binding fragment or conjugate disclosed herein disclosed herein is used in combination with alternating electric field therapy.

[0165] Also disclosed is a method for treating and / or diagnosing a disease or disorder that includes administering to a patient a therapeutic and / or diagnostic composition. The therapeutic and / or diagnostic composition includes any of the aforementioned compositions.

[0166] Analysis using a dataset from The Cancer Genome Atlas (TCGA) and histology analysis of over one hundred patient tissues revealed that Lipolysis-stimulated lipoprotein receptor (LSR) is overexpressed in most TNBCs, as well as ER+ / PR+ / HER2+ breast cancers. The anti-LSR mAb disclosed herein efficiently targeted and delivered potent chemotherapy to TNBC both in vitro and in vivo. LSR downregulation in endometrial cancer can inhibit cell proliferation; invasion and overexpression of LSR is associated with increased lipid uptake, cell proliferation, and / or upregulated cancer stem cell-like features. Overexpression of LSR can promote tumor development.

[0167] As disclosed herein, an anti-human LSR monoclonal antibody (mAb) was developed to target the extracellular domain (Metl-Asp259) of LSR (UniProtKB A0A8Z5ABK9). The anti-LSR mAb was further engineered by combining the variable region with Fc region of a human IgGl. The engineered mAb showed high surface, binding rate, and internalization for drug delivery in LSR+ TNBC, as confirmed by flow cytometry, confocal microscope images, and In Vivo Imaging System (IVIS).

[0168] An antibody-drug conjugate (ADC) disclosed herein was constructed by conjugating the LSR mAb with therapeutics including mertansine and other payloads. As disclosed herein, high in vitro anti-TNBC cytotoxicity and in vivo anti-tumor efficacy were observed in TNBC xenografted mouse models. No off-target or systemic toxicity was detected in the animal models.

[0169] The results shown herein disclose a new LSR-targeting therapy to treat cancers, as generally exemplified with TNBC. High expression of LSR was detected in TNBC cell lines and patient tissues. Leveraging this, new LSR mAb (“anti-LSR”) were developed, engineered and used to construct an ADC, including an antibody-mertansine (DM1) conjugate. The surfaceDocket No: T2025-304PCT (069596.00133)binding, internalization, and tumor targeting of the m Ab was validated using flow cytometry, confocal microscopy and In Vivo Imaging System (IVIS). The anti-LSR ADC was evaluated in vitro through cytotoxicity assays using three TNBC cell lines. Furthermore, anti- TNBC efficacy of the ADC was evaluated in two mouse models to assess tumor burden and tumor blockage. It was found that 24 mg / kg-BW of LSR mAb-DM1 reduced tumor burden by 85% in one model, while shrinking the tumor and blocking TNBC re-growth in a second model. Importantly, no off-target or systemic toxicity was detected in the animal models during and after treatment.Collectively, LSR is a promising target for cancers, including TNBC, and the LSR-targeting ADC offers a robust new therapeutic approach.EXAMPLES MATERIALS AND METHODS

[0170] The animal studies were conducted according to the Institutional Animal Care and Use Committee (IACUC) Protocol 2022A00000071 that was approved by the university Institutional Biosafety Committee.Cell lines and culture media

[0171] The human TNBC cell lines MDA-MB-231, MDA-MB-468, and MDA-MB-231-FLuc (ATCC, Manassas, VA, USA) were cultivated in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS, v / v) and 1% penicillin / streptomycin (Pen / Strep, v / v). The mouse TNBC cell lines 4T1 and 4Tl-FLuc (ATCC) were maintained in RPMI 1640 medium with 10% FBS and 1% Pen / Strep. The seed train of Expi293F cells for LSR mAb production was maintained in Expi293 Expression Medium containing 4 mM GlutaMAX and 4 g / L glucose. All cell cultures were incubated at 37°C in a humidified incubator with 5% CO2 (Caron, Marietta, OH, USA). Media and supplements were obtained from Fisher Scientific (Waltham, MA, USA) or Millipore Sigma (Burlington, MA, USA) unless otherwise specified.EXAMPLE 1Preparation and isolation of anti-LSR antibodyDevelopment, engineering, and production of anti-LSR mAb

[0172] First, the anti-human LSR mAb, targeting the Ig-like V-type extracellular domain (Metl-Asp259) of the surface receptor, was developed using the well-established hybridomaDocket No: T2025-304PCT (069596.00133)technology as previously described. Once mAb production was detected in the mice injected with immunogen, the splenocytes were collected and fused with myeloma cells Sp2 / 0-Agl4 (ATCC) to generate hybridoma cells. Two rounds of single cell cloning were performed to identify the top hybridoma clone with high affinity and mAb titer, quantified via enzyme-linked immunosorbent assay (ELISA) using the extracellular peptide as the coating antigen. Second, the top LSR mAb clone was engineered by fusing its variable region with the Fc region of a human IgGl for future clinical applications.

[0173] The engineered LSR mAb was produced from Expi293F cells using transient expression system (Gibco) fed with glucose (6 g / L) and L-GlutaMAX (6 mM). The antibody productions were performed in 2-L stirred-tank bioreactor with process parameters of Temp 37 °C, agitation 140 rpm, DO 40% and pH 7.2, or in a 3-L shaker flask at temp = 37 °C, agitation 130 rpm, and 8% CO2. Purification of LSR mAb was performed utilizing a Next Generation Liquid Chromatography system (Bio-Rad, Hercules, CA, USA). Specifically, the spent medium containing the mAb product was loaded onto 1-mL or 5- mL Bio-Scale Mini UNOsphere SUPrA affinity chromatography cartridges (Bio-Rad) with buffer A comprised of 0.02 M Na PO i and 0.02 M NasCeHsO? (pH 7.5). The mAb was eluted with buffer B comprised of 0.1 M NaCl and 0.02 M NaaCeHsCh (pH 3.0).EXAMPLE 2Construction and testing of antibody-drug conjugate comprising LSR mAb Construction of LSR mAb-DMl

[0174] The LSR mAb-DM1 ADC was constructed. Briefly, the purified LSR mAb was neutralized, desalted via buffer exchange, and concentrated to 5 mg / mL with a 10 kDa MWCO PES concentrator. During the conjugation reaction, 5 mg / mL mAb, 10 mg / mL sulfo-SMCC linker, and 10 mM of DM1 were mixed at a molar ratio of 1:14:18.2. After incubation at 37 °C for 2 hours, the constructed ADC was purified using a Protein A column, desalted using a 10 kDa Slide-A-Lyzer dialysis cassette, and further concentrated with a 10 kDa PES concentrator.Characterization of ADCs

[0175] The purity and drug-antibody ratio (DAR) of the ADC were analyzed using a High-Performance Liquid Chromatography (HPLC) system (Shimadzu, Columbia, MD, USA) equipped with a MAbPac hydrophobic interaction chromatography (HlC)-butyl column (5 pm,Docket No: T2025-304PCT (069596.00133)4.6x100 mm). Two aqueous mobile phases with flow rates of 1.0 mL / min were utilized: Buffer A, 1.5 M (NH4)2SO4and 50 mM Na3PO4at pH 7.0 and Buffer B, 50 mMNa3PO4at pH 7.0. UV / Vis spectroscopy was used to confirm ADC conjugation and mass spectrometry was used to quantitate DAR.In vitro cytotoxicity

[0176] The human and mouse TNBC cells were seeded in 96-well plates at densities of 10,000 cells (MDA-MB-468), 1,000 cells (MDA-MB-231), and 500 cells (4T1) per well. The cell sin each well were treated with LSR mAb-DM1 or free DM1 at final concentrations of 0, 2, 4, 10, 20, 50, 100, or 200 nM. After a 5-day incubation at 37°C and 5% CO2, relative viability was tested using the MTT Cell Proliferation Assay Kit. The absorbance at 570 nm was measured using a microplate reader (BioTek, Winooski, VT, USA).Flow cytometry analysis

[0177] The surface binding of engineered LSR mAb to TNBC MDA-MB-231, MDA-MB-468 and 4T1 cells was tested using flow cytometry. Specifically, the anti-LSR mAb was labeled with fluorescent Alexa Fluor™ 647 kit. Approximately 1 x 106TNBC cells were stained with 5 pg of LSR mAb-AF647 or saline (control) at 37°C for 60 minutes. After washing with PBS three times, the stained cells were analyzed on a BD LSRII flow cytometer (BD Biosciences, San Jose, CA, USA) and data were processed using FlowJo software. The gating was set so that the negative control (i.e. TNBC cells stained with saline) had <0.5% fluorescent population.Live-cell confocal microscopy

[0178] The internalization of LSR mAb into TNBC cells was assessed using live-cell confocal microscopy. Approximately 10,000 MDA-MB-468 cells were seeded in 35-mm glass-bottom dishes (Cellvis, Mountain View, CA, USA) in 1.5-mL of medium. The cytoplasm of cells was stained with BacMam GFP Transduction Control, and the nucleus was visualized with NucBlue™ Live Ready Probes Reagent following the manufacturer’s instructions. The LSR mAb labeled with cyanine-5.5 fluorescent dye (Lumiprobe, Hunt Valley, MD, USA) was added to TNBC cultures at a final concentration of 5 pg / mL and incubated for 12 hours. Live-cell images were acquired using an A1R-HD25 confocal microscope (Nikon, Melville, NY, USA).In vivo imaging system (IVIS)

[0179] The 6-week-old NOD SCID gamma (NSG) female mice (Jackson Lab, Bar Harbor, ME, USA) were subcutaneously (s.c.) injected with 10x106MDA-MB-231-FLuc cells toDocket No: T2025-304PCT (069596.00133)establish TNBC xenograft models. When tumor volumes reached -100 mm3, 80 jug of LSR mAb-Cy5.5 was administered intravenously (i.v.) via tail vein. After 24 hours, live-animal imaging was collected at an excitation / emission wavelength of 660 / 710 nm following intraperitoneal (i.p.) injection of the FLuc substrate luciferin. Mice were then sacrificed to collect major organs, such as brain, heart, lung, spleen, liver and kidneys, for ex vivo imaging.MDA-MB-231 xenografted models and treatment

[0180] A total of 10xl06MDA-MB-231-FLuc cells were s.c. injected into 6-week-old female NSG mice (Jackson Lab). Once tumor volumes reached -50 mm3, the mice were randomized into three groups (n = 6) and received i.v. administrations of saline (control), 12 mg / kg ADC, or 24 mg / kg ADC every three to four days (i.e. twice each week). Tumor dimensions were measured with a caliper and volumes were calculated using the formula (length x width2) / 2. IVIS imaging was also performed to monitor tumor growth. Mouse body weight was measured twice per week. At the end of the study, all tumor tissues and major organs, such as brain, heart, lung, kidneys, liver, and spleen, were collected for further post-treatment analysis.4T1 xenografted models and treatment

[0181] The 6-week-old BALB / cJ female mice were s.c. implanted with 2xl064Tl-FLuc cells per mouse. Tumor growth and body weight were monitored every three to four days (i.e. twice each week). When the average tumor volume reached -50 mm3, mice were randomized into two groups (n = 4) and i.v. injected with either saline (control) or 24 mg / kg ADC every three or four days. The study concluded when ulcerations reached 2 mm, after which tumors and organs were collected for further analysis.Immunohistochemistry (IHC) staining

[0182] A TNBC patient tissue microarray (TMA, Cat# BRI 102, TissueArray, Derwood, MD, USA) and normal organ tissue microarray (Cat# FDA662d, TissueArray) were stained with the engineered anti-LSR mAb following a standard IHC staining protocol. The stained TMA slides were scanned with a Lionheart FX automated microscope (BioTek, Winooski, VT, USA). LSR expression was quantified with ImageJ and the score was calculated using the formula ((red / blue)TNBc / (red / blue)Positive control)- l)x 100. High, medium, and low or no expression levels were defined as scores of >0.5, 0.5 to -0.5 and <-0.5 respectively, using positive control as baseline. Proliferation and apoptosis in the tumor microenvironment after treatment were evaluated using a similar IHC procedure to stain the tissue slides.Docket No: T2025-304PCT (069596.00133)TCGA transcript analysis

[0183] The LSR RNA data for breast cancers (TNBC, ER+ / PR+, HER2+) and normal breast tissue were obtained from The Cancer Genome Atlas (TCGA) via the UCSC Xena platform (https: / / xenabrowser.net / datapages / ). The raw expression data, originally in fragments per kilobase of transcript per million mapped reads (FPKM), were converted to transcripts per million (TPM) for normalization. Student’s t-test was conducted to assess the differential expression of LSR between various breast cancer subtypes and normal tissue.Western blotting

[0184] Lysates of TNBC cells were prepared using RIPA buffer and quantified using the Pierce protein assay kit. After separation on a NuPAGE 4-12% gradient SDS-PAGE gel, host cell proteins were transferred onto a PVDF membrane using a power supply (Bio-Rad Laboratories, CA, USA). The PVDF membrane was blocked in 5% non-fat milk in TBST buffer for 1 hour, stained with primary antibodies, i.e. engineered LSR mAb (2 pg / mL) or anti-P-tubulin antibody (1:1000, Abeam), overnight at 4°C, and washed three times with TBST. Following the washes, PVDF membrane was incubated with anti -human IgG-HRP (1:5000) or anti-rabbit IgG-HRP (1:3000) in 5% non-fat milk for 1 hour at room temperature. After color development, the washed PVDF membrane was imaged with Azure 300 imaging system (Azure Biosystems, Dublin, CA, USA).Hematoxylin and eosin (H& E) staining

[0185] Paraffin-embedded tumor and organ slides were dewaxed in xylene, rehydrated using a graded ethanol series (100% — > 50%) and distilled water, and stained with hematoxylin. After dipping in 1% HC1 and 70% ethanol, slides were immersed in 1% NHiOH for blue color development, followed by a 30-second eosin stain. Finally, the slides were dehydrated in 95% and 100% ethanol and cleared with xylene. Images of the H& E-stained slides were captured using a Lionheart FX Automated Microscope (BioTek, Winooski, VT, USA).Statistical analysis

[0186] Experimental data were analyzed and presented as mean ± standard error of the mean (SEM). Within-animal changes were evaluated using paired t-tests. Tumor growth and body weight were compared among groups using a two-way ANOVA followed by post-hoc (Dunnett’s) analysis. GraphPad Prism was used for statistical analysis, a significance thresholdDocket No: T2025-304PCT (069596.00133)of P-value< 0.05 was used for all tests. All adjusted / ’-values were calculated using the Benjamini -Hochberg method to control the FDR.Data and materials availability

[0187] All data generated during this study are included herein. Most materials used in the study, except the developed and engineered LSR mAb, are commercially available. The commercial NSG (NOD. Cg-PrkdcscldII2rgtmlw-'1 / SzJ) mice and BALB / cJ mice were purchased from Jackson Laboratory.RESULTS AND DISCUSSION LSR expression in TNBCs

[0188] Immunohistochemistry staining on a patient tumor microarray (TMA, n = 110) with the LSR antibody was used to evaluate LSR protein receptor expression in TNBC (Fig. 1A). Representative IHC images of tissue cores with varying levels of LSR expression are presented (Fig. IB). High LSR expression was detected in 35 patient tissues (32.7%) and medium expression was found in 32 tissue cores (29.9%), accounting for a total of 62.6% TNBC cases (Fig. IB). Notably, 37.4% of TNBC patients had low or minimal LSR expression, defined as LSR' case. These patients could benefit from therapies targeting other surface receptors, such as CD276 or EGFR. Without being bound by theory, heterogenous tumors containing portions of LSR' TNBC cells are still effectively targeted using combination strategies or dual-payload ADC, which delivers both highly potent chemotherapy and an immune boosting reagent.

[0189] LSR transcript expression was analyzed using a Cancer Genome Atlas (TCGA) dataset. As shown in Fig. 1C, LSR mRNA levels in TNBC are significantly higher than those in normal breast tissues. These transcript data are consistent with the protein expression analysis from the TMA, indicating that LSR could be a good target for therapy development. In addition to TNBC patients, ER+ / PR+patients and HER2+patients also showed high levels of LSR transcript expression. Therefore, targeting LSR could benefit multiple breast cancers subtypes.

[0190] LSR expression was further evaluated in TNBC cell lines (including human MDA-MB-231, and human MDA-MB-468 and mouse 4T1. Western blotting analysis revealed that LSR has high expression in all three cell lines (Fig. ID), which is consistent with the TMA protein expression analysis and TCGA transcript analysis. MDA-MB-231 and 4T1 were selected for anti-cancer cytotoxicity assessment in vitro and anti-TNBC efficacy studies in vivo.Docket No: T2025-304PCT (069596.00133)Collectively, these results are consistent with LSR as a promising target in TNBC and other breast cancer subtypes.Development and production of anti-LSR mAb

[0191] A new mAb was engineered to target the extracellular domain (Metl-Asp259) of human LSR (UniProtKB A0A8Z5ABK9). The top hybridoma clone 3C4A7, which had high mAb titer and binding affinity to domain of SEQ ID NO: 15 was selected for further development (Fig. 2A). After sequencing, the 3C4A7 clone was engineered by fusing its variable region with the Fc region of a human IgGl (Fig. 2B). The advantages of engineering the LSR mAb include circulation stability enhancement, Fc-mediated antibody effector function improvement, and minimal immunogenicity in future clinical application. The engineered LSR mAb was produced in fed-batch suspension culture using transient expression system. As shown in Fig. 2C, 41.6 mg / L of mAb was produced from a 9-day culture with maximum viable cell density (VCD) of 4.9xl06cells / mL. Glucose (4 g / L) and GlutaMAX (4 mM) were added to the production culture on Days 3 and 5. The high-purity mAb was purified using affinity purification with a liquid chromatography system (Fig. 2D).TNBC specificity and cross-species reactivity of LSR mAb

[0192] First, the surface binding of the engineered LSR mAb to TNBC was evaluated in human TNBC cell lines (MDA-MB-231 and MDA-MB-468) and a murine TNBC cell line (4T1) using flow cytometry (Fig. 3 A). The mAb showed high binding rates of 100% in MDA-MB-468, 95.6% in MDA- MB-231 and 73.3% in 4T1. The immunogen ofhuman LSR peptide (residues 89-259) shares 91% of amino acid sequence similarity with the corresponding extracellular region (residues 1-171) of mouse LSRUniProt: Q99KG5). Without being bound by theory, this is understood to explain the cross-species reactivity of the anti-human LSR mAb, although the binding to mouse TNBC was relatively lower. Targeting both human and mouse LSR enables future pre-clinical evaluations and makes mice a suitable animal model for in vivo evaluations. Additionally, IHC staining of TNBC patient tissues (Fig. 1A) confirmed the specificity of the chimeric anti-LSR mAb for human TNBC

[0193] Furthermore, mAb internalization in TNBC cells was assessed with live-cell confocal microscopy. As presented in Fig. 3B, the LSR mAb-Cy5.5 was detected in the cytoplasm of MDA-MB- 468 cells at 12 hours after incubation. The mAb is internalized via receptor-mediatedDocket No: T2025-304PCT (069596.00133)endocytosis and trafficked to late endosomes for lysosomal degradation, which releases the conjugated cytotoxic drugs into the cytoplasm, causing cell death.

[0194] Finally, the MDA-MB-231-FLuc xenografted mouse models were established to assess the in vivo TNBC-specific targeting and biodistribution of LSR mAb. Live-animal IVIS imaging displayed colocalization of Cy5.5 fluorescence signal (mAb) and FLuc bioluminescence signal (TNBC) 24 hours after tail vein injection (Fig. 3C). The ex vivo IVIS showed strong accumulation of LSR mAb (Cy5.5) in tumor while undetectable signal in brain, heart, lung, spleen, liver, and kidneys (Fig. 3D). These IVIS images demonstrated that the engineered LSR mAb selectively targets TNBC in vivo with minimal off-target effects, consistent with effectively deliver payloads for cancer treatment.In vitro cytotoxicity ofLSR-targetingADC

[0195] The LSR-targeting ADC was constructed by conjugating the mAb with DM1 via sulfo-SMCC linker (Fig. 4A). HPLC characterization of the ADC confirmed the homogenous conjugation of mAb and chemotherapy with a conversion rate of >95% (Fig. 4B). SDS-PAGE analysis confirmed the structural integrity of LSR ADC (Fig. 4C). The anti-TNBC cytotoxicity of free DM1 and LSR mAb-DMl ADC was evaluated in human and mouse TNBC cell lines. The mass spectrometry analysis showed that the drug to antibody ratio (DAR) of LSR ADC was 3.91 (FIG.4D). As presented in Fig. 4E, free DM1 exhibited IC50 values of 6.6 nM (4T1), 10.7 nM (MDA-MB-231) and 25.5 nM (MDA- MB-468). The IC50 values for LSR mAb-DM1 ADC were 46.0 nM (4T1), 43.1 nM (MDA-MB-231) and 35.5 nM (MDA-MB-468) (Fig. 4F). These cytotoxicity assay results illustrated that LSR-DM1 ADC can effectively kill TNBC cells in vitro. The ADC has lower cytotoxicity to TNBC cells than free drug at low concentrations of 10-40 nM, which can be explained by the multi-step (receptor binding, internalization, and drug release) targeted drug delivery process.Anti-TNBC efficacy in MDA-MB-231 xenograft models

[0196] The anti-cancer efficacy study was first conducted in human MDA-MB-231-FLuc xenografted NSG mice. As described in Fig. 5A, the TNBC tumor volumes reached 612.2 mm3(saline), 435.8 mm3(12 mg / kg-BW LSR mAb), 212.4 mm3(12 mg / kg LSR mAb-DMl ADC), and 95.7 mm3(24 mg / kg LSR mAb-DMl ADC) on Day 32. Compared to the saline group, LSR mAb reduced tumor burden by 29%, which could be attributed to the inhibition of lipid uptake or synthesis by the mAb. The ADC doses of 12 and 24 mg / kg reduced tumor burden by 65% andDocket No: T2025-304PCT (069596.00133)85%, respectively, indicating that this LSR-targeting therapy inhibited tumor growth in a dosedependent manner. TNBC tumor volume at the end of treatment was also evaluated using tumor FLuc flux (Fig. 5B). Consistent with the calculated tumor volume, 24 mg / kg of ADC significantly inhibited human TNBC growth in mouse models. The IVIS images, collected on Day 9 (prior to treatment started) and Day 31 (one day before the endpoint), illustrated that LSR mAb-DMl ADC inhibited tumor growth (Fig. 5C). H& E staining of paraffin-embedded tumor tissue sections after treatment revealed that tumor intensity decreased in the treatment group (Fig. 5D). IHC staining with anti-Ki67 (proliferation marker in cancer cells) antibody confirmed that TNBC cell proliferation was inhibited by ADC treatment (Fig. 5E).Anti-TNBC efficacy in 4T1 xenograft models

[0197] The mouse TNBC 4T1 xenografted BALB / cJ immunocompetent models were used to validate the anti-TNBC efficacy of the LSR mAb-DMl ADC. Treatment with 24 mg / kg ADC reduced tumor volume and caused tumor shrinkage (FIG. 6A) without affecting mouse body weight (Fig. 6B), suggesting minimal systemic toxicity. Live-animal IVIS images confirmed the effectiveness of ADC treatment (Fig. 6C), as indicated by the undetectable or weak FLuc signal in the treatment group. H& E staining of tumor tissues harvested at the end of the study revealed severe tumor cell death in ADC group (Fig. 6D), which was consistent with the tumor volume data in Figs. 6A and 6C. The tumor volume slightly increased on Days 18-20 in Fig. 6A, but the dead cells in H& E staining indicated that the increase could be caused by non- cellular factors (e g., inflammation, vascular formation, necrosis) instead of tumor growth recurrence. IHC staining of tumor sections showed that the ADC induced apoptosis, as indicated by the upregulation of cleaved caspase 3, and inhibited cancer cell proliferation, as displayed by the downregulation of Ki67 (Fig. 6E). In addition to the DM1 induced microtubule depolymerization, but without being bound by theory, it is expected that the anti-LSR mAb inhibit TNBC cell growth by reducing lipid uptake and thereby inhibiting cell membrane synthesis. The live-cell confocal microscopy revealed that the TNBC MDA-MB-231 cells treated with anti-LSR mAb had lower lipid uptake (Fig. 6F).Evaluation of toxicity

[0198] In the animal studies, treatment with 12 and 24 mg / kg-BW ADC did not result in a decrease in mouse body weight (Fig. 7A). H& E staining of major organs, including heart, brain, lung, liver, kidney and spleen, detected no inflammation, apoptosis, necrosis, or damage in theDocket No: T2025-304PCT (069596.00133)mAb or ADC groups (Fig. 7B). IHC staining of 33 normal human tissues (n = 2) using the engineered LSR mAh revealed no significant off-target binding, as confirmed by whole slide scanning (Fig. 7C). Additionally, the high- resolution images of heart, brain, lung, kidney and spleen did not show obvious binding of the engineered LSR mAb (Fig. 7D). While the liver tissue showed a weak signal, it is significantly lower that that observed in TNBC patient tissues. Although LSR has high expression in liver cells, particularly hepatocytes, post-translational modifications of its extracellular domain in the liver differ due to its metabolic role. Without being bound by theory, these variations can affect (e.g. reduce) the binding of the engineered LSR mAb. Overall, these results suggest that the LSR mAb effectively target LSR overexpressing TNBCs with minimal off-target effects on normal tissues.

[0199] The absence of effective cell surface receptors in TNBCs has hindered the development of new targeted therapies. Recently, Trop-2 and CD276 have emerged as promising therapeutic targets for TNBC and other cancers. Trop-2-targeting sacituzumab govitecan and datopotamab deruxtecan have been employed to treat breast and other malignancies, but their clinical efficacy remains limited in recurrent and metastatic settings. Recent clinical trials of GSK5764227 (HS-20093) and Ifinatamab deruxtecan (NCT06203210, NCT04145622) have evaluated their potential for treating prostate cancer and small cell lung cancer treatment, but trials in TNBC patients has not yet begun. Importantly, the extreme heterogeneity of TNBCs necessitates the exploration of additional surface markers to ensure broader therapeutic coverage. As disclosed herein, LSR is an alternative surface receptor. Dual targeting strategies, such as incorporating LSR together with Trop-2 or CD276 can also be employed therapeutically. The efficacy of LSR-targeted therapy was validated in TNBC mouse models, confirming its therapeutic potential. Beyond TNBC, LSR exhibits high transcript expressions in ER+ / PR+and HER2+breast cancer subtypes, suggesting its therapeutic potential across multiple breast cancer types.

[0200] The anti-LSR mAb developed herein shows targeted delivery vehicle for potent payloads. The mAb demonstrated high surface binding to TNBC cells in vitro and selective tumor targeting in vivo, with minimal off-target effects in normal human and mouse organs, enabling effective targeting of TNBC. The engineering and construction of the chimeric LSR mAb enhances its clinical value, based on improved circulation stability. Additionally, the anti-LSR ADC conjugated with a standard cytotoxic microtubule inhibitor DM1 significantly reducedDocket No: T2025-304PCT (069596.00133)tumor burden in two TNBC xenografted mouse models. No body weight loss or detectable systematic toxicity was observed, suggesting manageable side effects in future clinical applications. Notably, the mAb exhibited minimal binding to 33 normal human organs, with only weak signals in human liver and pancreas tissues, despite high physiological LSR expression in hepatocytes. This selectivity may stem from differences in post-translational modifications (PTMs) between tumors and normal cells, which could affect mAb binding efficacy. The anti-LSR mAb also demonstrated therapeutic impact as a standalone agent, slightly reducing tumor growth and inhibiting lipid uptake and synthesis.

[0201] Shown herein is a new antibody-drug conjugate to treat cancer, in particular TNBC as exemplified, with several advantages. The absence of promising cell surface receptors in TNBC has limited the development of new targeted therapies. While Trop-2 and CD276 have been reported as promising targets, neither receptor could cover all patients due to the high heterogeneity of TNBC. LSR has been shown to be a surface receptor that can be targeted in LSR1breast cancer patients, including TNBC, ER ' / PR', and HER2'. The new anti -LSR mAb, disclosed herein can selectively target LSR-positive TNBC cells in vitro and in vivo and effectively deliver chemotherapy intracellularly to TNBC cells with minimal toxicity. Moreover, the LSR mAb reduced lipid uptake and thereby inhibited cancer cell growth. Two animal models validated the high anti-TNBC efficacy of LSR mAb-DMl ADC, which as disclosed herein provides a new targeted therapy for cancers expressing LSR.

[0202] The in vivo evaluations of anti-TNBC efficacy demonstrated that the LSR mAb-DMl ADC reduced tumor growth, in particular the LSR-targeted ADC significantly inhibited TNBC tumor growth in two xenograft mouse models. It could not completely block it or kill all cancer cells in the TNBC xenografted immunocompromised mouse models; while tumor growth was completely suppressed in syngeneic models, 15% residual tumor volume persisted in immunocompromised models. Without being bound by theory, contributing factors could include but are not limited to: 1) the LSR ADC dose applied in the study may not have been optimal. 2) a single- payload (DM1) ADC may be insufficient against the rapidly proliferating TNBC tumors.3) the targeting or surface binding rate of LSR mAb to MDA-MB-231 was less than 100%, allowing residual cancer cells to continue proliferating. Further without being bound by theory, the following strategies enhance cancer treatment effectiveness: 1) optimizing pharmacokinetics and testing various doses, thereby identifying optimal treatment strategies for LSR mAb- DM1Docket No: T2025-304PCT (069596.00133)ADC; 2) using a dual-payload ADC platform, which conjugates two synergistic anti-cancer payloads to one mAh or conjugating synergistic anti-cancer agents (e.g., cytotoxic and immune-enhancing payloads) to a single mAb, thereby improving treatment efficacy; 3) targeting two (or more) receptors, such as EGFR or CD276 in addition to LSR, to achieve 100% binding to all cancer cells, including for example TNBC cells, as well as mitigate receptor relapse-driven resistance; 4) using combination therapy with multiple synergistic anti-cancer agents, immunotherapy, or gene therapy, to improve cancer cell clearance in vivo and additionally reduce risk of drug resistance. Additionally, advanced cleavable linkers with high plasma stability and cancer-specific payload release can enhance drug delivery efficiency.

[0203] LSR suppresses CD8+ T-cell activity in the tumor microenvironment; without being bound by theory, this may explain the enhanced efficacy in syngeneic models, where the ADC’s cytotoxic effects (via DM1) synergize with LSR mAb-mediated immune activation. High LSR expression correlates with poor prognosis in gastric, epithelial ovarian, and endometrial cancers, consistent with the broad applicability of anti-LSR mAb and ADC across multiple cancer types. Combining LSR-targeted ADC with existing therapeutic regimens as disclosed herein can yield synergistic effects.EXAMPLE 3Construction and testing of dual antibody-drug conjugate (Dual ADC) comprising LSR mAb

[0204] A DualADC, such as for example LSR mAb-SN-38 / IMQ* is prepared according to the synthetic steps (FIG. 8) Treat the antibody with tris(2-carboxyethyl)-phosphine (TCEP) to break the disulfide bond. Conjugate a chemotherapeutic agent, such as SN-38 with a bivalent linker, such as Mc-VC-PAB. React the mAb with SN-38-Mc-VC-PAB to conjugate the chemotherapeutic, yielding an ADC. React the ADC with a bivalent linker, such as Sulfo-SMCC, followed by reaction with IMQ* to yield a DualADC (FIG. 8). HPLC characterization confirms the successful conjugation of the double payload (IMQ* and SN-38). MS evaluation confirms the structure LSR mAb-SN-38 / IMQ*, based on correlation with expected MZ values. The integrity of mAb-SN-38 / IMQ* is confirmed in SDS-PAGE. Conjugation parameters can optimize solubility and stability.

[0205] Other dual ADC, including but not limited to anti-LSR mAb-MMAF / IMQ comprising different bivalent linkers such as when MMAF is bound to the mAb via a DBMDocket No: T2025-304PCT (069596.00133)linker and IMQ is bound to the mAb via a sulfo-SMCC linker or MMAF is bound to the mAb via a DBM linker and IMQ is bound to the mAb via a phosphine azide linker can be prepared according to the methods disclosed herein and in WO 2025 / 019334.

[0206] The cytotoxicity of free LSR mAb-SN-38 / IMQ* is tested using MDA-MB-231, MDA-MB-468 and 4T1 cells using free drugs, LSR mAb, and single payload ADCs as controls.SEQUENCES

[0207] The nucleic and amino acid sequences listed in the following sequence listing are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids, as defined in 37 C. F. R. 1.822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand.

[0208] SEQ ID NO: 1 is the amino acid sequence of the chimeric anti-human LSR mAb heavy chain (VH)(Signal peptide-7?7?7-CDRl-7?7?2-CDR2-777?3-CDR3-777? ):METDTLLL W VLLLW VPGSTG A A SGSEEE VKL VESGGGL VRPGGSPKLSCAASGYYYSSXA MSWVRQTPEKRLEmASIGRGGYYYYPDSVKGRFTISRDNARNILYLQMSSLRSEDTAMYFC ARGPNYYGSSYYAMDYIFGgG7SF77Y5

[0209] SEQ ID NO: 2 is an amino acid sequence encoding the VH constant region, which binds to FR4:SRASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ S SGL YSLS S VVT VP S S SLGTQT YICNVNHKP SNTKVDKK VEPK SCDKTHTCPPCP APELL GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPP SRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV DKSRWQQGNVF SC S VMHEALHNHYTQKSLSLSPGK

[0210] SEQ ID NO: 3 (HCDR1): GFTFSSYA

[0211] SEQ ID NO: 4 (HCDR2): GRGGTT

[0212] SEQ ID NO: 5 (HCDR3): ARGPNYYGSSYYAMDY

[0213] SEQ ID NO: 6 is an exemplary nucleic acid sequence encoding the VH(Signal peptide-7?7?7-CDRl-7?7?2-CDR2-777?3-CDR3-777? ):Docket No: T2025-304PCT (069596.00133)ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTCCAGGTTCCACT GGCGCCGCTAGCGGATCCGAATTCGAAGTGAAGCTGGTGGAGTCTGGGGGAGGCTTAG TGAGGCCTGGAGGGTCCCCGAAACTCTCCTGTGCAGCCTCTGGA’TT'CACT'TTCAGTAG CTATGCC4 TGTCTTGGGTTCGCCAGACTCCAGAGAAGAGGCTGGAGTGGGTCGCA TCCA TTGGTAGGGGTGGTACCACCTACTATCCAGACAGTGTGAAGGGCCGATTCACCATCTC CAGAGATAATGCCAGGAACATCCTGTACCTGCAAATGAGCAGTCTGAGGTCTGAGGACAC GGCCA TGTA 7ZZCZG7GCAAGAGGCCCCAATTACTACGGTAGTAGCTACTATGCTA TGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCA

[0214] SEQ ID NO: 7 is an exemplary nucleic acid sequence encoding the VH constant region, which binds to FR4:TCTAGAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGC ACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACC GGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGG CTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCA GCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACC AAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACC GTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACC CAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGT GAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGC ATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTC AGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAA GGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAG GGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACC AAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCC GTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGT GTTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAG GTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCA CTACACGCAGAAGAGCCTCTCCCTGTCTCCCGGGAAATGA

[0215] SEQ ID NO: 8 is the amino acid sequence of the chimeric anti-human LSR mAh light chain (VL) (Signal peptide- R7-CDRl-F7?2-CDR2- R3-CDR3-FA7):Docket No: T2025-304PCT (069596.00133)METDTLLLWVLLLWVPGSTGAASGSEFDZOA / TOFS5E515TGGFF777,CF / 45QDIKKYA / 4 WYQHKPGKGPRLLIHXTSALQPGIPSRFSGSGSGRDFSFSISNLEPEDIATYYCVQyWil TF GGGTKLEITR

[0216] SEQ ID NO: 9 is an amino acid sequence encoding the VL constant region, which binds to FR4:RADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQ DSKDSTYSMSS TLTLTKDE YERHNS YTCE ATHKT ST SPIVK SFNRNEC

[0217] SEQ ID NO: 10 (LCDR1): QDIKKY

[0218] LCDR2: YTS

[0219] SEQ ID NO: 12 (LCDR3 ): LQYDNLLT

[0220] SEQ ID NO: 13 is an exemplary nucleic acid sequence encoding the VL(Signal peptide-FF7-CDRl-FF2-CDR2-FF3-CDR3-FF4):ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTCCAGGTTCCACT GGCGCCGCYAGCGGAYGCGAAT CGACATCCAGATGACACAGTCTCCATCCTCACTGTC TGCATCTCTGGGAGGCAAAGTCACCATCACTTGCAAGGCAAGCCAAGACATTAAGAAG TATCTAGCTTGGTACCAACACAAGCCTGGAAAAGGTCCTAGGCTGCTCATACATTACACA TCTGCATE4CAGCCAGGCA TCCCATCAAGGTTCAGTGGAAGTGGGTCTGGGAGAGA PTTT TCCTTCAGCA TCAGCAACCTGGAGCCTGAAGA TA TTGCAACTTATTA 77G7CTACAGTAT GATAATCTTCTGACGTTCGGTGGAGGCACCAAGCTGGAAATCACACGG

[0221] SEQ ID NO: 14 is an exemplary nucleic acid sequence encoding the VL constant region, bound to FR4:CGGGCTGATGCTGCACCAACTGTATCCATCTTCCCACCATCCAGTGAGCAGTTAACA TCTGGAGGTGCCTCAGTCGTGTGCTTCTTGAACAACTTCTACCCCAAAGACATCAAT GTCAAGTGGAAGATTGATGGCAGTGAACGACAAAATGGCGTCCTGAACAGTTGGAC TGATCAGGACAGCAAAGACAGCACCTACAGCATGAGCAGCACCCTCACGTTGACCA AGGACGAGTATGAACGACATAACAGCTATACCTGTGAGGCCACTCACAAGACATCA ACTTCACCCATTGTCAAGAGCTTCAACAGGAATGAGTGTTAG

[0222] SEQ ID NO: 15 CTYQMTSTPTQPIV

[0223] It is to be understood that any given elements of the disclosed embodiments of the invention may be embodied in a single structure, a single step, a single substance, or the like.Docket No: T2025-304PCT (069596.00133)Similarly, a given element of the disclosed embodiment may be embodied in multiple structures, steps, substances, or the like. The foregoing description and accompanying drawings illustrate and describe certain processes, machines, manufactures, and compositions of matter, some of which embody the invention(s). Such descriptions or illustrations are not intended to limit the scope of what can be claimed, and are provided as aids in understanding the claims, enabling the making and use of what is claimed, and teaching the best mode of use of the invention(s). If this description and accompanying drawings are interpreted to disclose only a certain embodiment or embodiments, it shall not be construed to limit what can be claimed to that embodiment or embodiments. Any examples or embodiments of the invention described herein are not intended to indicate that what is claimed must be coextensive with such examples or embodiments. Where it is stated that the invention(s) or embodiments thereof achieve one or more objectives, it is not intended to limit what can be claimed to versions capable of achieving all such objectives. Any statements in this description criticizing the prior art are not intended to limit what is claimed to exclude any aspects of the prior art. Additionally, the disclosure shows and describes certain embodiments of the processes, machines, manufactures, compositions of matter, and other teachings disclosed, but it is to be understood that the teachings of the present disclosure are capable of use in various other combinations, modifications, and environments and is capable of changes or modifications within the scope of the teachings as expressed herein. Any section headings herein are provided only for consistency with the suggestions of 37 C. F. R. § 1.77 or otherwise to provide organizational queues. These headings shall not limit or characterize the invention(s) set forth herein.

[0224] Additional exemplary embodiments contemplated herein are as follows:

[0225] Embodiment 1. An isolated monoclonal antibody, comprising: a heavy chain variable region (VH); and a light chain variable region (VL), wherein the VH comprises a first heavy chain complementarity determining region (HCDR1), a second heavy chain complementarity determining region (HCDR2), and a third heavy chain complementarity determining region (HCDR3), wherein the VL comprises a first light chain complementarity determining region (LCDR1), a second light chain complementarity determining region (LCDR2), and a third light chain complementarity determining region (LCDR3).Docket No: T2025-304PCT (069596.00133)

[0226] Embodiment 2. An isolated monoclonal antibody of Embodiment 1, wherein HCDR1 comprises a sequence with at least 80% identity to SEQ ID NO: 3.

[0227] Embodiment 3. An isolated monoclonal antibody of Embodiment 1 or 2, wherein HCDR2 comprises a sequence with at least 80% identity to SEQ ID NO: 4.

[0228] Embodiment 4. An isolated monoclonal antibody of any of the previous Embodiments, wherein HCDR3 comprises a sequence with at least 80% identity to SEQ ID NO: 5.

[0229] Embodiment 5. An isolated monoclonal antibody of any of the previous Embodiments, wherein LCDR1 comprises a sequence with at least 80% identity to SEQ ID NO: 10.

[0230] Embodiment 6. An isolated monoclonal antibody of any of the previous Embodiments, wherein LCDR2 comprises the amino acid sequence YTS.

[0231] Embodiment 7. An isolated monoclonal antibody of any of the previous Embodiments, wherein LCDR3 comprises a sequence with at least 80% identity to SEQ ID NO: 12.

[0232] Embodiment 8. An isolated monoclonal antibody of any of the previous Embodiments, wherein HCDR1, HCDR2, and HCDR3 comprise an amino acid sequence at least 90% identical to SEQ ID NOs: 3, 4, and 5, respectively

[0233] Embodiment 9. An isolated monoclonal antibody of any of the previous Embodiments, wherein LCDR1 and LCDR3 comprise an amino acid sequence at least 90% identical to SEQ ID NOs: 10 and 12, respectively, optionally wherein LCD2 comprises YTS.

[0234] Embodiment 10. An isolated monoclonal antibody of any of the previous Embodiments, wherein HCDR1 comprises the sequence set forth as SEQ ID NO: 3.

[0235] Embodiment 11. An isolated monoclonal antibody of any of the previous Embodiments, wherein HCDR2 comprises the sequence set forth as SEQ ID NO: 4.

[0236] Embodiment 12. An isolated monoclonal antibody of any of the previous Embodiments, wherein HCDR3 comprises the sequence set forth as SEQ ID NO: 5.

[0237] Embodiment 13. An isolated monoclonal antibody of any of the previous Embodiments, wherein LCDR1 comprises the amino acid sequence set forth as SEQ ID NO: 10.

[0238] Embodiment 14. An isolated monoclonal antibody of the previous Embodiments, wherein LCDR2 comprises the amino acid sequence YTS.Docket No: T2025-304PCT (069596.00133)

[0239] Embodiment 15. An isolated monoclonal antibody of the previous Embodiments, wherein LCDR3 comprises the amino acid sequence set forth as SEQ ID NO: 12.

[0240] Embodiment 16. An isolated monoclonal antibody of any of the previous Embodiments, wherein the VH comprises an amino acid sequence at least 80% or at least 90% identical to the amino acid sequence set forth as SEQ ID NO: 1.

[0241] Embodiment 17. An isolated monoclonal antibody of any of the previous Embodiments, wherein the VL comprises an amino acid sequence at least 80% or at least 90% identical to the amino acid sequence set forth as SEQ ID NO: 8.

[0242] Embodiment 18. An isolated monoclonal antibody of any of the previous Embodiments, wherein the VH comprises the amino acid sequence set forth as SEQ ID NO: 1.

[0243] Embodiment 19. An isolated monoclonal antibody of any of the previous Embodiments, wherein the VL comprises the amino acid sequence set forth as SEQ ID NO: 8.

[0244] Embodiment 20. An isolated monoclonal antibody of any of the previous Embodiments, comprising a human framework region

[0245] Embodiment 21. An isolated monoclonal antibody of any of the previous Embodiment, comprising a human constant domain.

[0246] Embodiment 22. An isolated monoclonal antibody of any of the previous Embodiments, wherein the antibody is a human antibody.

[0247] Embodiment 23. An isolated monoclonal antibody of any of the previous Embodiments, wherein the antibody is a humanized antibody.

[0248] Embodiment 24. An isolated monoclonal antibody of any of the previous Embodiments, wherein the antibody is a chimeric antibody.

[0249] Embodiment 25. An isolated monoclonal antibody of any of the previous Embodiments, wherein the antibody binds to Lipolysis-Stimulated Lipoprotein Receptor (LSR).

[0250] Embodiment 26. An isolated monoclonal antibody of any of the previous Embodiments, wherein the antibody is conjugated to an effector molecule.

[0251] Embodiment 27. An isolated antigen binding fragment of the antibody of any of the previous Embodiments, wherein the antigen binding fragment comprises the VH and the VL of the antibody.Docket No: T2025-304PCT (069596.00133)

[0252] Embodiment 28. An isolated antigen binding fragment of the antibody of any one of the previous Embodiments, wherein the antigen binding fragment comprises the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of the antibody.

[0253] Embodiment 29. The antigen binding fragment of Embodiment 27 or 28 conjugated to an effector molecule.

[0254] Embodiment 30. The antigen binding fragment of any of Embodiments 27-29, wherein the antibody binding fragment binds to Lipolysis-Stimulated Lipoprotein Receptor (LSR).

[0255] Embodiment 31. An isolated nucleic acid molecule encoding the antibody of any of Embodiments 1-26.

[0256] Embodiment 32. An isolated nucleic acid molecule encoding the antigen binding fragment of any of Embodiments 27-30.

[0257] Embodiment 33. The nucleic acid molecule of Embodiment 31 or 32, wherein the nucleic acid molecule is a recombinant nucleic acid molecule.

[0258] Embodiment 34. The nucleic acid molecule of any of Embodiments 31-33, wherein the nucleic acid molecule comprises a cDNA sequence.

[0259] Embodiment 35. The nucleic acid molecule of any of Embodiments 31-33, wherein the nucleic acid molecule comprises an RNA molecule.

[0260] Embodiment 36. The nucleic acid molecule of any of Embodiments 31-33, further comprising a promoter.

[0261] Embodiment 37. The nucleic acid molecule of any of Embodiment 31-36, comprising a DNA sequence at least 80% or at least 90% identical to the sequence set forth as SEQ ID NO: 6.

[0262] Embodiment 38. The nucleic acid molecule of any of Embodiment 31-37, comprising a DNA sequence at least 80% or at least 90% identical to the sequence set forth as SEQ ID NO: 13.

[0263] Embodiment 39. The nucleic acid molecule of any of Embodiment 31-38, comprising a DNA sequence set forth as SEQ ID NO: 6.

[0264] Embodiment 40. The nucleic acid molecule of any of Embodiment 31-39, comprising a DNA sequence set forth as SEQ ID NO: 13.Docket No: T2025-304PCT (069596.00133)

[0265] Embodiment 41. An expression vector comprising the nucleic acid molecule of any one of Embodiments 31-40.

[0266] Embodiment 42. A composition comprising: an effective amount of the monoclonal antibody of any one of Embodiments 1-26; and a pharmaceutically acceptable carrier; wherein the composition is optionally for use in treating cancer.

[0267] Embodiment 43. A composition of Embodiment 42 further comprising a pharmaceutically active agent.

[0268] Embodiment 44. A composition comprising: an effective amount of the antigen binding fragment of any of Embodiments 27-30; and a pharmaceutically acceptable carrier; wherein the composition is optionally for use in treating cancer.

[0269] Embodiment 45. A composition of Embodiment 44 further comprising a pharmaceutically active agent.

[0270] Embodiment 46. An antibody-drug conjugate comprising the monoclonal antibody of any one of Embodiments 1-26 conjugated to a first pharmaceutically active agent via a first bivalent linker; and a pharmaceutically acceptable carrier

[0271] Embodiment 47. An antibody-drug conjugate of Embodiment 46, wherein the first pharmaceutically active agent is a chemotherapeutic agent.

[0272] Embodiment 48. An antibody-drug conjugate of Embodiment 46, wherein the first pharmaceutically active agent is selected from monomethyl auristatin E (MMAE), monomethyl auri statin F (MMAF), emtansine (or mertansine (DM1)), Dxd (Exatecan derivative), SN-38, pyrrol obenzodi azepine dimer (PBD dimer, GD-1882), calicheamicin, spliceostatin A and combinations thereof.

[0273] Embodiment 49. The antibody-drug conjugate of Embodiment 46, wherein the first pharmaceutically active agent is an immunotherapy agent.

[0274] Embodiment 50. The antibody-drug conjugate of Embodiment 49, wherein the second pharmaceutically active agent is a toll-like receptor 7 / 9 (TLR 7 / 8) agonist.

[0275] Embodiment 51. The antibody-drug conjugate of Embodiment 50, wherein the TLR 7 / 8 agonist comprises an imidazoquinoline, optionally TLR7 / 8 Agonist 1 (IMQ), IMQ*, gardiquimod, resiquimod, R848*, or combinations thereof.Docket No: T2025-304PCT (069596.00133)

[0276] Embodiment 52. An antibody-drug conjugate of any of Embodiments 46-51, wherein the monoclonal antibody is conjugated to a second pharmaceutically active agent, optionally via a second bivalent linker.

[0277] Embodiment 53. The antibody-drug conjugate of Embodiment 52, wherein the second pharmaceutically active agent is an immunotherapy agent.

[0278] Embodiment 54. The antibody-drug conjugate of Embodiment 52, wherein the second pharmaceutically active agent is a toll-like receptor 7 / 9 (TLR 7 / 8) agonist.

[0279] Embodiment 55. The antibody-drug conjugate of Embodiment 54, wherein the TLR 7 / 8 agonist comprises an imidazoquinoline, optionally TLR7 / 8 Agonist 1 (IMQ), IMQ*, gardiquimod, resiquimod, R848*, or combinations thereof.

[0280] Embodiment 56. An antigen binding fragment-drug conjugate comprising the antigen binding fragment of Embodiment 15 or 16 conjugated to a first pharmaceutically active agent via a first bivalent linker.

[0281] Embodiment 57. The conjugate of Embodiments 26, wherein the first pharmaceutically active agent is a chemotherapeutic agent.

[0282] Embodiment 58. The conjugate of any of Embodiments 56-57, wherein the antigen binding fragment is conjugated to a second pharmaceutically active agent, optionally via a second bivalent linker.

[0283] Embodiment 59. The conjugate of Embodiment 58, wherein the second pharmaceutically active agent is an immunotherapy agent.

[0284] Embodiment 60. The conjugate of any of Embodiments 46-59, wherein the bivalent linker, such as the first or second bivalent linker, independently comprises a phosphine-azide linker, aN- succinimidyl S-acetylthioacetate sulfo-succinimidyl-4-(A-maleimidomethyl)-cyclohexane-1 -carboxylate (SATA sulfo- SMCC) linker, a sulfo- succinimidyl-4-(A-maleimidomethyl)cyclohexane-l-carboxylate (sulfo-SMCC) linker, or a dibromomaleimide (DBM) linker.

[0285] Embodiment 61. The conjugate of Embodiment 60, wherein the DBM linker comprises maleimide, DBM-Gly-Gly-Phe-Gly, DBM-GGG, DMB-Gly-Gly-Phe-Gly-P AB-OH, DBM-Val-Cit-PABC-PNP, or DBM-Val-Cit-PAB.

[0286] Embodiment 62. A pharmaceutical composition comprising the conjugate of any of Embodiments 46-61.Docket No: T2025-304PCT (069596.00133)

[0287] Embodiment 63. The pharmaceutical composition further comprising a pharmaceutically active agent, such as an anticancer agent.

[0288] Embodiment 64. A method of treating a disease susceptible to LSR inhibition in a patient in need thereof, wherein the method comprises administering to the patient a therapeutically effective amount of the antibody of any one of Embodiments 1-26, the composition of 42-45, the conjugate any one of Embodiments 46-61 or the composition of Embodiment 62 or 63.

[0289] Embodiment 65. A method of treating cancer in a subject in need thereof comprising: disposing the antibody of any one of Embodiments 1-26, the composition of 42-45, the conjugate any one of Embodiments 46-61 or the composition of Embodiment 62 or 63 within a biological compartment of the subject.

[0290] Embodiment 66. The method of Embodiment 65, wherein the cancer is endometrial cancer, gastric cancer, breast cancer or epithelial cancer.

[0291] Embodiment 67. The method of Embodiment 65 or 66, wherein the cancer is triple negative breast cancer or epithelial ovarian cancer.

[0292] Embodiment 68. The method of any of Embodiments 64-67, further comprising administering an anticancer agent.

[0293] Embodiment 69. The method of any of Embodiment 64-68, further comprising administering immunotherapy or gene therapy.

[0294] Embodiment 70. The method of Embodiment 68 or 69, wherein the anti cancer agent targets EGFR, CD276, or Trop-2.

[0295] Embodiment 71. The method of Embodiment 70, wherein the anticancer agent targeting EGFR comprises an anti-EGFR antibody; the anticancer agent targeting CD276 comprises anti-CD276 antibody; the anticancer agent targeting Trop-2 comprises an anti-Trop-2 antibody.

[0296] References

[0297] Abbar B, Aboubakar Nana F, Spano JP, Cadranel J, Gougis P. Sacituzumab govitecan: a new hope for patients with pretreated extensive small-cell lung cancer (SCLC)-insights from the TROPiCS-03 trial. Transl Lung Cancer Res. May 302025; 14(5): 1887- 1891. doi:10.21037 / tlcr-2025-216Docket No: T2025-304PCT (069596.00133)

[0298] Ahn MJ, Tanaka K, Paz-Ares L, et al. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-LungOl Study. J Clin Oncol. Jan 202025;43(3):260-272. doi: 10.1200 / JCO-24-01544

[0299] Amendola M, Squires JE. Pediatric Genetic Cholestatic Liver Disease Overview. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, eds.GeneReviews((R)). 1993.

[0300] Bardia A. New data for sacituzumab govitecan-hziy in the treatment of metastatic triple-negative breast cancer. Clin Adv Hematol Oncol. Nov 2021; 19(11):723-725.

[0301] Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2 -negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. May 1 2007;109(9):1721-8. doi:10.1002 / cncr.22618

[0302] Borri F, Granaglia A. Pathology of triple negative breast cancer. Semin Cancer Biol. Jul 2021;72:136-145. doi:10.1016 / j.semcancer.2020.06.005

[0303] Carey LA, Loirat D, Punie K, et al. Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis. NPJ Breast Cancer. Jun 92022;8(l):72. doi:10.1038 / s41523-022-00439-5

[0304] Chen K, Ernst P, Kim S, et al. An Innovative Mitochondrial -targeted Gene Therapy for Cancer Treatment. bioRxiv. Mar 272024;doi:10.1101 / 2024.03.24.584499

[0305] Chen K, Si Y, Guan JS, et al. Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma. Biomedicines. Jan 72022; 10(1): 130-144. doi:10.3390 / biomedicinesl0010130

[0306] Chen K, Si Y, Ou J, et al. Antibody-Drug Conjugate to Treat Meningiomas.Pharmaceuticals (Basel). May 22021;14(5):427-439. doi:10.3390 / phl4050427

[0307] Cicin I, Karatekin B, Guzelaltuncekic E, Kolbas I. Evaluation of sacituzumab govitecan for advanced / metastatic non-small cell lung cancer. Expert Rev Anticancer Ther. Aug 2025;25(8):845-852. doi:10.1080 / 14737140.2025.2515989

[0308] Ferrari P, Scatena C, Ghilli M, Bargagna I, Lorenzini G, Nicolini A. Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC. Int J Mol Sci. Jan 31 2022;23(3)doi:10.3390 / ijms23031665Docket No: T2025-304PCT (069596.00133)

[0309] Freedman RA, Heiling HM, Li T, et al. Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022. Ann Oncol. Nov 2024;35(l l):993-1002. doi:10.1016 / j.annonc.2024.07.245

[0310] Funauchi M, Serada S, Hiramatsu K, et al. Tumor cell-expressed lipolysis-stimulated lipoprotein receptor negatively regulates T-cell function. Int J Cancer. Feb 1 2024;154(3):425-433. doi: 10.1002 / ijc.34738

[0311] Hiramatsu K, Serada S, Enomoto T, et al. LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake. Cancer Res. Jan 15 2018;78(2): 516-527. doi: 10.1158 / 0008-5472. CAN- 17-0910

[0312] Hosni R, Klumper N, Sanders C, et al. The antibody-drug conjugate sacituzumab govitecan (IMMU-132) represents a potential novel therapeutic strategy in cholangiocarcinoma. Mol Cancer Ther. Jun 13 2025;doi:10.1158 / 1535-7163. MCT-24-0972

[0313] Hurvitz SA, Bardia A, Punie K, et al. Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer. Apr 25 2024;10(l):33. doi:10.1038 / s41523-024-00635-5

[0314] Jiang Y, Qian Z, Wang C, et al. Targeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer. J Immunother Cancer. Apr 122025; 13(4)doi: 10.1136 / jitc-2024-010924

[0315] Jin M, Fang J, Peng J, et al. PD-1 / PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies. Mol Cancer. Nov 292024;23(l):266. doi: 10.1186 / s 12943 -024-02176-8

[0316] Kanda M, Serada S, Hiramatsu K, et al. Lipolysis-stimulated lipoprotein receptor-targeted antibody-drug conjugate demonstrates potent antitumor activity against epithelial ovarian cancer. Neoplasia. Jan 2023;35: 100853. doi: 10.1016 / j. neo.2022.100853

[0317] Kawabata K, Takahashi T, Tanaka K, et al. Lipolysis-stimulated lipoprotein receptor promote lipid uptake and fatty acid oxidation in gastric cancer. Gastric Cancer. Nov 2024;27(6): 1258- 1272. doi: 10.1007 / s 10120-024-01552-z

[0318] Khadela A, Morakhia KR, Shah NH, et al. Sacituzumab govitecan in HER2-negative breast cancer: redefining treatment paradigms. J Drug Target. Jul 22025:1-14.doi: 10.1080 / 1061186X.2025.2525372Docket No: T2025-304PCT (069596.00133)

[0319] Kunert R, Reinhart D. Advances in recombinant antibody manufacturing. Appl Microbiol Biotechnol. Apr 2016;100(8):3451-6L doi:10.1007 / s00253-016-7388-9

[0320] Li H, Chang Y, Jin T, Zhang M. Progress of PD-1 / PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer. Cancer Cell Int. Apr 10 2025;25(l): 139. doi:10.1186 / sl2935-025-03769-z

[0321] Masuda S, Oda Y, Sasaki H, et al. LSR defines cell corners for tricellular tight junction formation in epithelial cells. J Cell Sci. Feb 152011;124(Pt 4):548-55.doi: 10.1242 / jcs.072058

[0322] Nagase Y, Hiramatsu K, Funauchi M, et al. Anti-lipolysis-stimulated lipoprotein receptor monoclonal antibody as a novel therapeutic agent for endometrial cancer. BMC Cancer. Jun 21 2022;22(l):679. doi:10.1186 / sl2885-022-09789-6

[0323] Narvekar P, Berriel Diaz M, Krones-Herzig A, et al. Liver-specific loss of lipolysis-stimulated lipoprotein receptor triggers systemic hyperlipidemia in mice. Diabetes. May 2009; 58(5): 1040-9. doi: 10.2337 / db08-l 184

[0324] Nedeljkovic M, Damjanovic A. Mechanisms of Chemotherapy Resistance in TripleNegative Breast Cancer-How We Can Rise to the Challenge. Cells. Aug 222019;8(9)doi: 10.3390 / cells8090957

[0325] Nguyen X, Hooper M, Borlagdan JP, Palumbo A. A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer. Ann Pharmacother. Nov 2021; 55( 11): 1410- 1418. doi:10.1177 / 1060028021998320

[0326] Ou J, Si Y, Gah KY, et al. Process development of antibody-drug conjugation production for cancer treatment. PLOS ONE.2018;https: / / doi.org / 10.1371 / journal.pone.0206246(13(10)):e0206246.

[0327] Ou J, Si Y, Tang Y, et al. Novel biomanufacturing platform for large-scale and high-quality human T cells production. JBiol Eng. 2019;13:34-46. doi:10.1186 / sl3036-019-0167-2

[0328] Papavassiliou KA, Sofianidi AA, Papavassiliou AG. The Attractiveness of B7-H3 as a Target for Lung Cancer Treatment. Cancers (Basel). May 12025; 17(9)doi: 10.3390 / cancers 17091546

[0329] Polakis P. Antibody Drug Conjugates for Cancer Therapy. Pharmacol Rev. Jan 2016;68(l):3-19. doi:10.1124 / pr. H4.009373Docket No: T2025-304PCT (069596.00133)

[0330] Reaves DK, Fagan-Solis KD, Dunphy K, Oliver SD, Scott DW, Fleming JM. The role of lipolysis stimulated lipoprotein receptor in breast cancer and directing breast cancer cell behavior. PLoS One. 2014;9(3):e91747. doi:10.1371 / journal.pone.0091747

[0331] Reaves DK, Hoadley KA, Fagan-Solis KD, et al. Nuclear Localized LSR: A Novel Regulator of Breast Cancer Behavior and Tumorigenesis. Mol Cancer Res. Feb 2017; 15(2): 165-178. doillO.l 158 / 1541-7786. MCR-16-0085-T

[0332] Rossi V, Turati A, Rosato A, Carpanese D. Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back. Front Immunol. 2024;15:1447280.doi: 10.3389 / fimmu.2024.1447280

[0333] Saito K, Konno T, Kohno T, et al. LSR antibody promotes apoptosis and disrupts epithelial barriers via signal pathways in endometrial cancer. Tissue Barriers. Jul 32023;l l(3):2106113. doi: 10.1080 / 21688370.2022.2106113

[0334] Sands J, Ahn MJ, Lisberg A, et al. Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study. J Clin Oncol. Apr 2025;43(10): 1254-1265. doi:10.1200 / JCO-24-01349

[0335] Saunders LR, Bankovich AJ, Anderson WC, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. Aug 262015;7(302):302ral36. doi:10.1126 / scitranslmed.aac9459

[0336] Schipilliti FM, Drittone D, Mazzuca F, La Forgia D, Guven DC, Rizzo A.Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer. Heliyon. Apr 15 2024;10(7):e28385. doi:10.1016 / j.heliyon.2024.e28385

[0337] Schlam I, Tarantino P, Tolaney SM. Managing adverse events of sacituzumab govitecan. Expert Opin Biol Ther. Jul-Dec 2023;23(ll):l 103-1111.doi: 10.1080 / 14712598.2023.2267975

[0338] Schreiber AR, O'Bryant CL, Kabos P, Diamond JR. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan. Expert Rev Anticancer Ther. Jul-Dec 2023;23(10): 1061-1069.doi:10.1080 / 14737140.2023.2257885Docket No: T2025-304PCT (069596.00133)

[0339] Shastry M, Jacob S, Rugo HS, Hamilton E. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer. Breast. Dec 2022;66:169-177. doi: 10.1016 / j.breast.2022.10.007

[0340] Shen Q, Zhou K, Lu H, et al. Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer. Discov Oncol. Dec 222024;15(l):822. doi:10.1007 / sl2672-024-01674-x

[0341] Shimada H, Kohno T, Konno T, et al. The Roles of Tricellular Tight Junction Protein Angulin-l / Lipolysis-Stimulated Lipoprotein Receptor (LSR) in Endometriosis and Endometrioid-Endometrial Carcinoma. Cancers (Basel). Dec 172021; 13(24)doi: 10.3390 / cancers 13246341

[0342] Shimada H, Satohisa S, Kohno T, et al. The roles of tricellular tight junction protein lipolysis-stimulated lipoprotein receptor in malignancy of human endometrial cancer cells.Oncotarget. May 102016;7(19):27735-52. doi:10.18632 / oncotarget.8408

[0343] Si Y, Chen K, Ngo HG, et al. Targeted EV to Deliver Chemotherapy to Treat TripleNegative Breast Cancers. Pharmaceutics. Jan 72022; 14(1) doi:10.3390 / pharmaceuticsl4010146

[0344] Si Y, Guan J, Xu Y, et al. Dual-Targeted Extracellular Vesicles to Facilitate Combined Therapies for Neuroendocrine Cancer Treatment. Pharmaceutics. 2020; 12(11): 1079-1090.

[0345] Si Y, Kim S, Ou J, et al. Anti-SSTR2 Antibody-drug Conjugate for Neuroendocrine Tumor Therapy. Cancer Gene Therapy. Cancer Gene Therapy. 2020;28:799-812.

[0346] Si Y, Kim S, Zhang E, et al. Targeted Exosomes for Drug Delivery:Biomanufacturing, Surface Tagging, and Validation. Biotechnol J. Oct 92019; 15: 1900163-1900174. doi: 10.1002 / biot.201900163

[0347] Si Y, Xu Y, Guan J, et al. Anti-EGFR antibody-drug conjugate for triple-negative breast cancer therapy. Eng Life Sci. Jan 2021;21(l-2):37-44. doi: 10.1002 / elsc.202000027

[0348] Si Y, Zhang Y, Guan J-S, et al. Anti-CD47 Monoclonal Antibody-drug Conjugate: A Targeted Therapy to Treat Triple-negative Breast Cancers. Vaccines. 2021;9:882-895.

[0349] Si Y, Zhang Y, Ngo H, et al. Targeted liposomal chemotherapies to treat triplenegative breast cancer. Cancers. 2021;13:3749-3763.Docket No: T2025-304PCT (069596.00133)

[0350] Spring LM, Nakajima E, Hutchinson J, et al. Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxi cities. Oncologist. Oct 2021;26(10):827-834. doi: 10.1002 / onco.13878

[0351] Stenger C, Hanse M, Pratte D, et al. Up-regulation of hepatic lipolysis stimulated lipoprotein receptor by leptin: a potential lever for controlling lipid clearance during the postprandial phase. FASEB J. Nov 2010;24(l l):4218-28. doi: 10.1096 / fj.10-160440

[0352] Sugase T, Takahashi T, Serada S, et al. Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer. Oncotarget. Aug 31 2018;9(68):32917-32928. doi:10.18632 / oncotarget.25952

[0353] Takahashi Y, Serada S, Ohkawara T, et al. LSR promotes epithelial ovarian cancer cell survival under energy stress through the LKB1-AMPK pathway. Biochem Biophys Res Commun. Jan 222021;537:93-99. doi: 10.1016 / j.bbrc.2020.12.079

[0354] Torchia A, Ciappina G, Giammaruco M, Monteferrante I, Landi L, Cappuzzo F. Antibody -Based Therapeutics in Small Cell Lung Cancer: A Narrative Review. Biologies.2025;19:189-199. doi:10.2147 / BTT. S500460

[0355] van den Ende NS, Nguyen AH, Jager A, Kok M, Debets R, van Deurzen CHM.Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review. Int J Mol Sci. Feb 3 2023;24(3)doi:10.3390 / ijms24032969

[0356] Voges L, Weiss F, Branco AT, Fromm M, Krug SM. Expression and Localization Profiles of Tight Junction Proteins in Immune Cells Depend on Their Activation Status. Int J Mol Sci. Apr 292024;25(9)doi: 10.3390 / ijms25094861

[0357] von Arx C, De Placido P, Caltavituro A, et al. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer. Cancer Treat Rev. Feb 2023; 113:102500. doi: 10.1016Zj.ctrv.2022.102500

[0358] Wespiser M, Gille R, Perol M. Clinical progress of B7-H3 targeted antibody drug conjugate ifinatamab deruxtecan for small-cell lung cancer. Expert Opin Investig Drugs. May 29 2025: 1-9. doi: 10.1080 / 13543784.2025.2512566

[0359] Xu N, Ma C, Ou J, et al. Comparative Proteomic Analysis of Three Chinese Hamster Ovary (CHO) Host Cells. Biochem Eng J. Aug 15 2017;124:122-129.doi:10.1016 / j.bej.2017.05.007Docket No: T2025-304PCT (069596.00133)

[0360] Xu N, Ou J, Gilani AK, Zhou L, Liu XM. High-Level Expression of Recombinant IgGl by CHO KI Platform. Frontiers of Chemical Science & Engineering. 2017;9(3):376-380.

[0361] Xu N, Ou J, Si Y, et al. Proteomics insight into the production of monoclonal antibody. Biochemical Engineering Journal. 2018:https: / / doi.org / 10.1016 / j.bej.2019.02.022.

[0362] Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. Jun 92020;22( 1):61. doi: 10.1186 / sl 3058-020-01296-5

[0363] Zhou L, Xu N, Sun Y, Liu XM. Targeted biopharmaceuticals for cancer treatment. Cancer Lett. Oct 01 2014;352(2): 145-51. doi:10.1016 / j.canlet.2014.06.020

[0364] Zhou ZZ, Si Y, Zhang J, et al. A Dual-Payload Antibody-Drug Conjugate Targeting CD276 / B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer. Cancer Res. Nov 15 2024;84(22):3848-3863. doi:10.1158 / 0008-5472. CAN-23-4099

Claims

1. Docket No: T2025-304PCT (069596.00133)CLAIMS1. An isolated monoclonal antibody, comprising:a heavy chain variable region (Vn); anda light chain variable region (VL);wherein the Vn comprises a first heavy chain complementarity determining region (HCDR1), a second heavy chain complementarity determining region (HCDR2), and a third heavy chain complementarity determining region (HCDR3);wherein the Vi, comprises a first light chain complementarity determining region (LCDR1), a second light chain complementarity determining region (LCDR2), and a third light chain complementarity determining region (LCDR3); andwherein(a) HCDR1 comprises a sequence with at least 80% identity to SEQ ID NO: 3, HCDR2 comprises a sequence with at least 80% identity to SEQ ID NO: 4; and HCDR3 comprises a sequence with at least 80% identity to SEQ ID NO: 5; and / or (b) LCDR1 comprises a sequence with at least 80% identity to SEQ ID NO: 10;LCDR2 comprises the amino acid sequence YTS; andLCDR3 comprises a sequence with at least 80% identity to SEQ ID NO: 12.

2. The antibody of claim 1, wherein(a) HCDR1 comprises the sequence set forth as SEQ ID NO: 3, HCDR2 comprises the sequence set forth as SEQ ID NO: 4, and HCDR3 comprises the sequence set forth as SEQ ID NO: 5, and / or(b) LCDR1 comprises the sequence set forth as SEQ ID NO: 10; LCDR2 comprises the sequence YTS; and LCDR3 comprises the sequence set forth as SEQ ID NO: 12.

3. The antibody of claim 1, wherein(a) the VH comprises a sequence with at least 80% identity to the sequence set forth as SEQ ID NO: 1; and / or(b) the VL comprises a sequence with at least 80% identity to the sequence set forth as SEQ ID NO: 8.Docket No: T2025-304PCT (069596.00133)4. The antibody of claim 1, wherein:(a) the VH comprises the sequence set forth as SEQ ID NO: 1; and / or(b) the VL comprises the sequence set forth as SEQ ID NO: 8.

5. The antibody of claim 1, comprising (i) a human framework region and / or (ii) a human constant domain.

6. The antibody of claim 1, wherein the antibody is a human antibody.

7. The antibody of claim 1, wherein the antibody is a humanized antibody.

8. An isolated antigen binding fragment of the antibody of any one of claims 1-7, wherein the antigen binding fragment comprises the VH and VL of the antibody and binds to Lipolysis- Stimulated Lipoprotein Receptor.

9. An isolated nucleic acid molecule encoding the antibody of any one of claims 1-7.

10. The isolated nucleic acid molecule of claim 9, wherein the nucleic acid molecule is a recombinant nucleic acid molecule.

11. The isolated nucleic acid molecule of claim 9, wherein the nucleic acid molecule comprises a cDNA sequence encoding the antibody.

12. The isolated nucleic acid molecule of claim 9, wherein the nucleic acid molecule comprises an RNA molecule encoding the antibody.

13. The isolated nucleic acid molecule of claim 9, further comprising a promoter.

14. The isolated nucleic acid molecule of claim 9, comprisingDocket No: T2025-304PCT (069596.00133)(a) a DNA sequence at least 80% identical to the sequence set forth as SEQ ID NO: 6 and / or(b) a DNA sequence at least 80% identical to the sequence set forth as SEQ ID NO: 1315. The isolated nucleic acid molecule of claim 9, comprising:(a) a DNA sequence set forth as SEQ ID NO: 6 and / or(b) a DNA sequence set forth as SEQ ID NO: 13.

16. An expression vector comprising the nucleic acid molecule of claim 9.

17. A method of treating a disease susceptible to Lipolysis-Stimulated Lipoprotein Receptor (LSR) inhibition in a patient in need thereof, wherein the method comprises administering to the patient a therapeutically effective amount of the monoclonal antibody of any one of claims 1-7.

18. A composition comprising:an effective amount of the monoclonal antibody of any one of claims 1-7; anda pharmaceutically acceptable carrier, optionally further comprising a pharmaceutically active agent.

19. An antibody-drug conjugate comprisingthe monoclonal antibody of any one of claims 1-7 conjugated to a first pharmaceutically active agent via a first bivalent linker.

20. The antibody-drug conjugate of claim 19, wherein the first bivalent linker comprises a phosphine-azide linker, a N- succinimidyl S-acetylthioacetate sulfo-succinimidyl-4-(A-maleimidomethyl)-cyclohexane-l -carboxylate (SATA sulfo-SMCC) linker, a sulfo-succinimidyl-4-(A-maleimidomethyl)cyclohexane-l-carboxylate (sulfo-SMCC) linker, or a dibromomaleimide (DBM) linker.Docket No: T2025-304PCT (069596.00133)21. The antibody-drug conjugate of claim 20, wherein the DBM linker comprises maleimide, DBM-Gly-Gly-Phe-Gly, DBM-GGG, DMB-Gly-Gly-Phe-Gly-P AB-OH, DBM-Val-Cit-PABC-PNP, or DBM-Val-Cit-PAB.

22. The antibody-drug conjugate of claim 19, wherein the first pharmaceutically active agent is a chemotherapeutic agent.

23. The antibody-drug conjugate of claim 19, wherein the first pharmaceutically active agent is selected from monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), emtansine (or mertansine (DM1)), Dxd (Exatecan derivative), SN-38, pyrrolobenzodiazepine dimer (PBD dimer, GD-1882), calicheamicin, spliceostatin A and combinations thereof.

24. The antibody-drug conjugate of claim 19, whereinthe monoclonal antibody is conjugated to a second pharmaceutically active agent via a second bivalent linker.

25. The antibody-drug conjugate of claim 24, wherein the second bivalent linker comprises a phosphine-azide linker, a N- succinimidyl S-acetylthioacetate sulfo-succinimidyl-4-(A-maleimidomethyl)-cyclohexane-l -carboxylate (SATA sulfo-SMCC) linker, a sulfo-succinimidyl-4-(A-maleimidomethyl)cyclohexane-l-carboxylate (sulfo-SMCC) linker, or a dibromomaleimide (DBM) linker.

26. The antibody-drug conjugate of claim 25, wherein the DBM linker comprises maleimide, DBM-Gly-Gly-Phe-Gly, DBM-GGG, DMB-Gly-Gly-Phe-Gly-P AB-OH, DBM-Val-Cit-PABC-PNP, or DBM-Val-Cit-PAB.

27. The antibody-drug conjugate of claim 24, wherein the second pharmaceutically active agent is an immunotherapy agent.

28. The antibody-drug conjugate of claim 27, wherein the immunotherapy agent is a toll-like receptor 7 / 8 (TLR 7 / 8) agonist.Docket No: T2025-304PCT (069596.00133)29. The antibody-drug conjugate of claim 28, wherein the TLR 7 / 8 agonist comprises IMQ, IMQ*, gardiquimod, resiquimod, R848*, or combinations thereof.

30. A pharmaceutical composition comprising the antibody-drug conjugate of any of claims 19-29 and a pharmaceutically acceptable carrier.

31. A method of treating a disease susceptible to Lipolysis-Stimulated Lipoprotein Receptor (LSR) inhibition in a patient in need thereof, wherein the method comprises administering to the patient a therapeutically effective amount of the antibody-drug conjugate of any one of claims 19-29.

32. A method for treating cancer in a subject in need thereof comprising:disposing the antibody-drug conjugate of any one of claims 19-29 within a biological compartment of the subject.

33. The method of claim 32, wherein the cancer is endometrial cancer, gastric cancer, breast cancer, or epithelial cancer.

34. The method of claim 32, wherein the cancer is triple negative breast cancer.

35. The method of claim 32, wherein the cancer is epithelial ovarian cancer.

36. The method of claim 32, further comprising administering an anticancer agent.

37. The method of claim 36, wherein the anticancer agent targets EGFR, CD276, or Trop-2.

38. The method of claim 37, wherein the anticancer agent targeting EGFR comprises an anti-EGFR antibody; the anticancer agent targeting CD276 comprises anti-CD276 antibody; the anticancer agent targeting Trop-2 comprises an anti-Trop-2 antibody.